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ABSTRACT

THE ANTITUMOR AGENT, ARGLABIN-DMA, PREFERENTIALLY INDUCES
APOPTOSIS IN HUMAN COLON TUMOR CELLS
Sung Wook Kwon
Old Dominion University, 2005
Director: Dr. Christopher J. Osgood

Arglabin-DMA, an analog o f famesyl pyrophosphate (FPP), reportedly inhibits
famesyltransferase (FTase) directly by competitively blocking the binding o f Ras protein
and its posttranslational modification, as suggested in previous studies. But, the
mechanisms by which Arglabin-DMA inhibits tumor growth in vivo and in vitro are still
relatively poorly characterized. To determine the mechanism by which this drug inhibits
tumor growth, the effects o f Arglabin-DMA in two human colon tumor cell lines (mutant
K-ras HCT 116 and wild-type ras HT-29) were explored on cell proliferation, apoptosis,
and cell cycle kinetics in vitro. In cell viability studies, we showed that Arglabin-DMA
had striking morphological and physiological effects on the two human colon tumor cell
lines, possibly more so than those o f other anticancer drugs. Also, Arglabin-DMA
exhibited less harm to normal cells (Hs27) which retained their potential for cell growth.
An add-back experiment showed that Arglabin-DMA had no effect on the isoprenoid
biosynthetic pathway. The drug not only affects the mutant K-ras human colon tumor cell
line, but also the wild-type ras human colon tumor cell line. It may therefore inhibit one
or more non-Ras proteins to exert its antitumor effects. Gel electrophoresis, TUNEL
assay, Annexin V assay, apoptosis dye-uptake assay, and morphological criteria were
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used to characterize apoptosis. Adherent cells and freely floating detached cells in
Arglabin-DMA treatment were treated as two distinct populations. We demonstrated that
the detached cells caused by Arglabin-DMA exposure exhibited increased apoptosis in a
p53-independent manner. Cell cycle effects were studied using flow cytometry. After
Arglabin-DMA was added, the proportion o f the two human colon tumor cells in G 2 /M
phase increased, indicating a block in either G 2 or M phase. We conclude that ArglabinDMA has specific cytotoxic effects in two human colon tumor cell lines, and less
cytotoxicity to normal cells. It induces arrest at the G 2 /M phase o f the cell cycle. After
treatment with Arglabin-DMA, rounded and detached cells enter apoptosis. This
mechanism may be analogous to "anoikis," which is the induction o f apoptosis in
response to loss o f cell contact. The utility o f this drug in combating cancer remains an
attractive, though complex possibility.
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INTRODUCTION

1. CANCER AND RAS

Normal cells grow, divide, and die in an orderly fashion. The cells o f most tissues
divide only to replace worn-out or dying cells, or to repair injuries. However, cancer cells
continue to grow and divide, exhibiting uncontrolled growth. They can spread to other
parts o f the body via the bloodstream, or lymph system. These cells accumulate and form
tumors.

Different types o f cancers, named for the organ or type o f cell in which they
originated, vary in their rates of growth, patterns o f dispersal, and responses to different
types o f treatment. That is why people with cancer require treatment that is targeted
towards their specific form of the disease. The number o f treatment choices depends on
the type o f cancer, the stage o f the cancer, and other individual factors such as age, health
status, and personal preferences.

Presently, the three major types o f treatment for cancer are surgery, radiation, and
chemotherapy. Chemotherapy involves the use o f drugs to kill tumor cells. The several
classes o f chemotherapeutic drugs act by various means, most frequently by inhibiting
the ability o f tumor cells to divide. Therapeutic drugs are commonly used in combination

The model for this dissertation is British Journal o f Cancer.
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2
to attack these tumors, as these cells are less able to withstand a variety o f agents
attacking in different ways. The compounds may be introduced into the body
systemically, or they may be concentrated at the tumor site (Ampil et al., 1999).

New approaches for chemotherapy were developed using the characteristic
molecular abnormalities o f cancers. Recently, researchers have studied the molecular
defects that transform normal cells into malignant cells. They found that many o f these
defects consist o f mutations in key classes o f genes that are responsible in some way for
the growth and replication o f cells (Gatenby and Maini, 2002). These mutations alter the
behavior o f proteins encoded by growth-regulating genes and disrupt the functions that
control cell division. The discovery o f mutant genes is enabling pharmaceutical
researchers to design new drugs that will act specifically on these disrupted genes, or
their proteins. The defects targeted by molecular therapy are found in three classes o f
genes: oncogenes, which stimulate cell progression through the cell cycle; tumor
suppressor genes restricting this growth; and genes governing the replication and repair
o f DNA. Most tumors possess mutations in one or more o f these gene categories (Oliff,
1999).

A detailed understanding o f the mechanisms by which genetic mutations appear
to have increased cancerous risk to the cell is anticipated to result in mechanism-based
cancer therapeutics. These therapies specifically target the underlying defects in cellular
growth regulation. Compared to current chemotherapeutic agents, these alternative
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therapeutics may prove to be much less toxic and more effective, thus possibly producing
superior therapeutic results. One potential target is the Ras protein, which is mutationally
activated in a large range o f human tumors and is an important contributor to the
neoplastic phenotype (Bos, 1998; Rowinsky et a i, 1999).

The Ras superfamily consists o f over 150 small GTPase proteins. This
superfamily contains monomeric proteins that bind GDP (guanine diphosphate) and GTP
(guanine triphosphate) and may be found in the plasma membrane and nuclear envelope.
Within the superfamily there are six subfamilies: Ras, Rho, Ran, Rab, Arf, and Kir/Rem.
Although many Ras members can interact with the same effector molecules, the
physiological roles o f most Ras-like GTPases are not fully understood (Bos, 1997;
Ehrhart et al., 2002).

The distinct members of the Ras superfamily are involved in a wide diversity of
cellular functions, the Ras and Rho groups being o f special interest. Both the Ras and
Rho families mediate key cellular processes in response to diverse stimuli such as cell
growth, differentiation, apoptosis, lipid metabolism, cytoarchitecture, membrane
trafficking, and transcriptional regulation. However, the negative aspect o f these
multifunctional proteins arises by way o f point mutations, overexpression, or insensitivity
to regulatory signals. This results from the ability o f these GTPases to trigger specific
signals, which lead to uncontrolled cell growth, enhanced angiogenesis, inhibition of
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apoptosis, and genetic instability. Collectively, these mutations can result in tumor
development (Rechavi et al., 1989; Vermes and Haanen, 1994).

The members o f Ras family, at least 13 at present, are characterized by extensive
similarities in their effector domains (Lowy and Willumsen, 1993). Besides three Ras
proteins (H-Ras, K-Ras, and N-Ras) that share about 85% sequence identity, two other
Ras proteins (M-Ras and R-Ras), four Rap proteins (RaplA , Rap IB, Rap2A, and Rap2B),
two Ral proteins (RalA and RalB), TC21, and Rheb are classified in the Ras family. The
other members, except the three Ras proteins (H-Ras, K-Ras, and N-Ras), share at least
40-50% amino acid identity with p21 Ras (Adjei, 2001; Beaupre and Kurzrock, 1999).
The Ras family as a whole acts as molecular switches that regulate a wide range o f cell
functions, including proliferation and differentiation (Gibbs et al., 1994; Moores et al.,
1991; Tamanoi, 1993).

The Rho family o f proteins share at least 30% sequence identity, and include
several members: Rho A, Rho B, Rho C, Rho D, Rho E, Rho G, TC10, Rac 1A, Rac IB,
Rac 2, CDC42Hs, and G25K (Takai et al., 1995). These proteins play critical roles in the
regulation o f the cytoskeleton as well as in signal transduction o f different stimuli
(Hernandez-Alcoceba et al., 2000; Takai et al., 2001).

Ras and Rho family members exhibit a carboxy-terminal CAAX motif, where a
cysteine is followed by two aliphatic residues and one random amino acid. This m otif is a
target for processing by enzymes, which results in the addition o f a carboxy-terminal
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prenyl group. Either a farnesyl or a geranylgeranyl moiety is involved in anchoring Ras
to membranes (Casey, 1995). Inhibitors o f the enzymes involved in this prenylation
process show promise as inhibitors o f Ras function by blocking its localization to the
plasma membranes (Ehrhardt et al., 2002; Reuter et al., 2000).

In isoprenoid biosynthesis in mammalian cells, the FPP (farnesyl pyrophosphate)
comprises 15 carbon chains. Also two molecules o f the 10-carbon GPP (geranyl
pyrophosphate) combine to form the 20-carbon GGPP (geranylgeranyl pyrophosphate)
(Adjei, 2001). GPP and FPP are intermediates in the synthesis o f monoterpenes and
sesquiterpenes. Assorted monoterpenes and sesquiterpenes posttranscriptionally downregulate HMG-CoA (3 -hydroxy-3-methyglutaryl coenzyme A) reductase activity, a key
activity in the isoprenoid biosynthetic pathway (the mevalonate pathway). The
isoprenoid-mediated suppression o f mevalonate synthesis depletes tumor tissues o f two
intermediate products, GGPP and FPP, which are incorporated posttranslationally into
growth control-associated proteins. Isoprenoids targeted to the inhibition o f the
isoprenylation o f oncogenic forms o f ras proteins may offer a novel approach to
chemotherapy (Elson, 1995) (Figure 1).

Two mevalonic acid pathway intermediates, GGPP and FPP, are substrates for
protein isoprenyl transferases. These enzymes catalyze the formation o f thioester bonds
between the carbon chains o f isoprenyl pyrophosphates and cysteine residues located
near the carboxy terminals of a variety o f proteins that include the nuclear lamins and the
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Figure 1 The isoprenoid biosynthetic pathway. Mevalonate is used as a precursor in
metabolic labeling studies. Lovastatin blocks this pathway by the inhibition o f HMGCoA (3-hydroxy-3-methyglutanyl coenzyme A) reductase. GPP (Geranyl pyrophosphate),
FPP (farnesyl pyrophosphate), and GGPP (geranylgeranyl pyrophosphate) are produced
from mevalonate. FPP is responsible for the post-translational modification and
membrane targeting o f Ras protein, whereas GGPP is responsible for those o f Rho family
small GTP-binding protein. FTI (Famesyltransferase inhibitor) or GGTI
(Geranylgeranyltransferase Inhibitor) block famesylation or geranylgeranylation to
modify Ras or Rho. FPP is an intermediate in the synthesis o f sesquiterpenes. Some
sesquiterpenes like Arglabin-DMA inhibit famesylation. (Elson, 1995; Holstein et al.,
2002; Maltese, 1990).
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small and large G-proteins (Clarke, 1992). The development o f inhibitors targeted to the
Ras protein famesyltransferase (FTase) offers an approach to the control o f the growth of
certain tumors (Goldstein and Brown, 1990).

The oncogenic ras genes in human cells have been identified, and are called Hras, 'H-ras, and K-rav. These ras oncogenes encode four 21-kD proteins, called P21ras or
Ras (H-Ras, N-Ras, and K-Ras4A and K-Ras4B, resulting from two alternatively spliced
K-ras gene products) (Rowinsky et al., 1999). Ras proteins consist o f 188 or 189 amino
acids that are highly conserved in the N and C termini. Most o f the differences between
these proteins occur in the near C-terminal hypervariable domain o f about 25 amino acids,
which is presumed to be responsible for their different functions (Adjei, 2001).

Ras is synthesized as a propeptide which undergoes a series o f posttranslational
lipid modifications that enable it to associate with the inner surface o f the plasma
membrane. The first step in posttranslational modification is mediated by FTase (farnesyl
transferase), which transfers a farnesyl moiety from FPP to the cysteine moiety in the
CAAX m otif at the carboxyl terminus o f Ras (Rowinsky et al., 1999) (Figure 2). After
famesylation, CAAX proteins undergo cleavage o f the AAX by CAAX protease. The
exposed carboxyl group o f the famesyl-cysteine is carboxymethylated by a SAM (Sadenosyl-L-methionine) donor. In some Ras proteins, palmitoyl transferase catalyzes an
additional modification of upstream cysteine residues by the fatty acid palmitate. These
modifications enhance protein hydrophobicity and plasma membrane association (Adjei,
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Figure 2 Ras posttranslational modification. The first step is mediated by
famesyltransferase (FTase), which transfers a farnesyl moiety from farnesyl
pyrophosphate (FPP) to the cysteine moiety in the CAAX m otif at the carboxyl terminus
o f Ras. FTase inhibitions block this enzymatic step (Rowinsky et al., 1999).
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2001; Gibbs and Oliff, 1997). A closely related enzyme, protein GGTase (geranylgeranyl
transferase), recognizes the C-terminal CaaX m otif present in proteins such as Rho A.
After geranylgeranylation that transfers a geranylgeranyl moiety from GGPP to the
cysteine moiety in the CAAX m otif at the carboxyl terminus o f target protein, these
proteins undergo modifications that facilitate membrane association similar to Ras
posttranslational lipid modifications (Tamanoi et al., 2001) (Figure 3). Many mammalian
proteins, besides the four forms o f Ras, have a CAAX m otif and are substrates for either
FTase or GGTase (Rowinsky et al., 1999) (Table 1).

Ras is activated in response to a variety o f extracellular signals resulting in
stimulation o f tyrosine protein kinases, either directly or indirectly. Ras proteins function
as molecular switches, and are determined by whether they are bound to GDP or GTP,
conferred by the small GTPase (Ehrhardt et al., 2002). The small GTPase, which cycles
between active GTP-bound and inactive GDP-bound states, is activated by GEFs
(guanine nucleotide exchange factors). GEFs include the SOS (son o f sevenless) proteins
and Cdc25. In the receptor tyrosine kinase cascade, the adaptor protein, Grb2 (growth
factor receptor-binding protein), binds to activated receptors via its SH2 domain, then
recruits GEFs to the cell membrane via its SH3 domain (Takai et al., 2001). In its GTPbound state, Ras interacts with several downstream effector pathways which contain
multiple internal branch points. R af is one o f many effectors o f Ras signaling. Other
effectors include proteins Rac and Rho, and PI3K (phosphatidylinositol-3’-kinase), and
MEKK (mitogen-activated protein kinase kinase kinase). The activation o f the effector
R af phosphorylates MEK (mitogen-activated protein kinase kinase), which in turn
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Table 1 Famesylated or geranylgeranylated CAAX proteins
Farnesylated CAAX Protein(s)
Geranylgeranylated CAAX Protein(s)
H-ras, K4B-Ras, and N-ras
G-proteins y-subunits
Lamins A and B
Rap 1
Rap2
Rho A, B, C, and G
R hoE
Cdc42
Pxf
Rac 1 and 2
R-Ras 1 and R-Ras 2/TC21
Phosphorylase kinase a and (5
PRL-1/PTP CAAX 1 and 2
Ral A and B
Transducin y
cGMP phosphodiesterase (3
2’-3’ ologo (A) synthetase 3’cGMP phosphodiesterase a
phosphodiesterase
Rhodopsin kinase
Inosito-1,4,5-triphosphate 5phosphatase type 1
YDJ1 homolog
Inositol-1,4,5-triphosphate
5-phosphatase type 1
Mammalian CAAX proteins that are known or likely to be prenylated. Data adapted from
(Rowinsky et al., 1999).
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phosphorylates MAPK (mitogen-activated protein kinase), and ERK (extracellular signalregulated kinase). Upon activation, MAPKs/ERKs stimulate transcription and
proliferation. MEKK activates SEK1, which in turn phosphorylates another MAPK
family number, JUN (jun amino-terminal kinase). It promotes apoptosis and proliferation.
Activation o f Rac and Rho also regulates cytoskeletal organization. PI3K signaling has
been linked to a number o f cellular processes (Adjei, 2001; Rowinsky et al., 1999)
(Figure 4). Ras activation leads to enhanced signal transduction pathways that mediate
the cell cycle, and plays a role in the proliferation o f cells. It also leads to the activation
of other types o f signals ranging from upstream o f receptor tyrosine kinases to a
downstream cascade o f protein kinases. These kinases control a wide variety o f cellular
processes including mitogenic signaling, cellular differentiation, nuclear localization,
cytoskeleton rearrangement, and apoptosis (Adjei, 2001; Lowy and Willumsen, 1993).

Mutant oncogenic ras genes are frequent genetic aberrations found in 20% to 30%
o f all human tumors, although the incidences by tumor type vary greatly. The highest
incidence o f Ras mutations was detected in adenocarcinomas o f the pancreas, the colon,
and the lung (Reuter et al., 2000). Mutated ras oncogenes were first identified by their
ability to transform NIH 3T3 cells after DNA transfection. Subsequent analysis o f a
variety o f tumor samples revealed that in each tumor, one o f the three ras genes harbored
a point mutation (Rowinsky et al., 1999) (Table 2). Mutation o f K-ras is most commonly
found in human tumors, whereas N -ras mutations are encountered less often and H-ra.v
mutations are encountered rarely (Oliff, 1999). Mutations o f the K-ras gene are found
exclusively in colon, lung, and pancreatic cancers. In cancers o f the kidney, bladder, and
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(Rowinsky et al., 1999).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

14

Table 2 Ras mutation in human tumors
Tumor Type

Ras Mutation (%)

23-30
Acute myelogenous leukemia
10
Bladder
2
Breast
>50
Cholangiocarcinoma
Colon
36
Adenocarcinoma
Adenoma
24-50
44
Colorectal
Endometrial carcinoma
18-40
10-30
Liver
Lung
Large-cell carcinoma
21-33
Adenocarcinoma
22-50
10
Kidney
5-15
Melonoma
Ovarian carcinoma
23
Pancreatic carcinoma
>80
43
Seminoma
26
Skin: keratoacanthoma
Thyroid
Follicular adenoma
28
Follicular carcinoma
53
Undifferentiated carcinoma
60
(H, H-ras; K, K-ras; N, N-ra.v) Data adapted from (Adjei, 2001;
1999; Rowinsky et al., 1999).

Predominant m s
Mutation
N
H
H, K
N
K
K
K
K
N
K
K
H
N
K
K
K, N
H
H, K, N
H, K, N
H, K, N
Beaupre and Kurzrock,
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skin, mutations are primarily in the H-ras gene, while mutations in the N-rav gene are
consistently found in cases o f leukemia (Adjei, 2001; Beaupre and Kurzrock, 1999).
Thyroid carcinomas are unique in having mutations in one o f the three ras genes. Most
mutationally activated forms of ras genes identified in tumors result in disrupted guanine
nucleotide regulation and constitutive activation o f Ras (Lowy and Willumsen, 1993;
Rowinsky et al., 1999).

To inhibit constitutive activation o f Ras in tumors, researchers have focused on
the inhibition of FTase. Initial approaches to FTase inhibition involved the use o f general
inhibitors o f isoprenylation. Synthesis o f famesyl groups can be blocked by HMG-CoA
reductase inhibitors and the mevalonate pyrophosphate decarboxylase inhibitor (Adjei,
2001). Currently, a new class o f antitumor drug has been described that targets the
posttranslational modification o f the Ras protein crucial for its activity (Gibbs et al.,
1994). Several different FTIs (FTase inhibitors) have been identified that competitively
inhibit FTase by distinct biochemical mechanisms and can be placed into three major
categories. The first o f the general approaches has used design and synthesis o f FPP
analogs that compete with the substrate FPP for FTase (Tamanoi et al., 1993). The
second class o f FTIs is designed to mimic the Ras C terminus. The CAAX portion o f Ras,
starting at cysteine, contains all the critical determinants necessary for interaction with
the enzyme FTase (Moores et al., 1991). The final class o f drugs combines the properties
o f the peptidomimetics and the famesyl pyrophosphate analogs, and has therefore been
termed bisubstrate inhibitor analogs (Manne et al., 1995).
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Ras protein is one o f the primary target proteins o f chemotherapy. It ordinarily
behaves as a relay switch within the signal pathway that tells the cell to divide. It does
this in response to external stimuli and results in activation o f the signaling pathway.
Activation o f the ras protooncogene plays a role in the formation o f cancers in the
pancreas, the lung, and the colon (Bos, 1989). Even though there is some evidence to
suggest that this oncogene influences the differentiation and proliferation o f normal cells,
as well as apoptotic processes, its precise role in malignancy is still unclear (Darley et al.,
1997). Ras has already been implicated in cell-signaling pathways o f apoptosis, induced
by various stimuli such as TN F-a (tumor necrosis factor-a), FAS, viral infection, and
mechanical stress. Activation o f Ras depends on both the inducer and the cell type; it will
either inhibit or promote apoptosis (Billadeau et al., 1995; Gulbins et al., 1996; Trent et
al., 1996).

2. ARGLABIN-DMA

Sesquiterpenes are the largest class o f terpenoids, and their structures are more
diverse than any other class of terpenes. They are a widespread group o f substances
occurring in various plant species. Many sesquiterpene lactones have already been
identified from the family Compositae, in particular Genera Ixeris, Lactuca, Artemisia,
and Cicholium (Chung, 2001). The therapeutic properties o f the Artemisia species,
belonging to the Asteraceae family, are well known in the traditional pharmacopoeia o f
Europe, North America, and Asia (Klayman et al., 1984; Norvaretti and Lemordant,
1990).
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Sesquiterpene lactones inhibit a large number o f enzymes involved in key
biological processes such as DNA and RNA synthesis, purine systhesis, glycolysis, the
citric acid cycle and the mitochondrial electron transport chain (Beekman et al., 1997;
Page et al., 1987). They have been extensively used due to their wide variety o f
biological applications, which include: treatment o f migraines and inflammation;
cytotoxic and/or antitumor activities; shared the antibiotic property to act as phytotoxins,
mammalian toxins, and insect-feeding deterrents; and also their ability to cause allergic
contact dermatitis (Wen et al., 2002). The cytotoxic and antitumor effects o f
sesquiterpene lactones have not been well studied due to their low potency. Recently it
has been reported that some sesquiterpene lactones inhibit the in vitro growth o f tumor
cells in a cytostatic fashion, and it has been proposed that if their selectively cytotoxic or
cytostatic actions against tumor cells can be established, sesquiterpene lactones may
represent a new class of cancer chemotherapeutic drugs (Ross et al., 1999).

Arglabin [ 1(R), 10(S)-epoxy-5(S), 6 (S), 7(S)-guaia-3(4), ll(13)-dien-6,12-olide]
(Figure 5), a sesquiterpene y-lactone, was isolated in the early 1980s from the aerial part
o f the plant, Artemisia glabella, a species o f wormwood endemic to the Karaganda
region o f Kazakhstan (Shaikenov et al., 1998; Shaikenov et al., 2001). The monoterpene
limonene blocks cellular protein prenylation and causes the differentiation o f tumor cells
(Crowell et al., 1991, Haag et al., 1992). Arteminolode, a sesquiterpene lactone from
Artemisia rulvatica, showed selective inhibitory activity against rat FTase (Lee et al.,
1998). Therefore, the structural similarity with cellular isoprenoids makes natural
terpenoids attractive for development o f inhibitors o f protein prenylation, in particular,
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Figure 5 Structure o f Arglabin and Arglabin-DMA. The sequiterpene y-lactone
Arglabin, which isl(R ), 10(S)-epoxy-5(S), 6 (S), 7(S)-guaia-3(4), 1 l(13)-dien-6, 12-olide
(A), and water soluble dimethylaminohydrochloride derivative o f Arglabin (ArglabinDMA) (B) (Shaikenov et al., 2001).
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inhibition o f FTase and the oncogenic activation or the Ras protein (Shaikenov et al.,
1999). Arglabin is a derivative o f famesyl pyrophosphate, which is a substrate for FTase,
and has structural similarity with cellular polyprenols (Epstein et al., 1991). Initial
investigations focused on the ability o f Arglabin to inhibit polyprenylation o f cellular
proteins because sesquiterpenes are made from farnesyl pyrophosphate (Shaikenov et al.,
1998).

The natural plant compound Arglabin is transformed by phosphorylation within
cells, and this phosphoryiated derivative can prevent famesylation o f Ras proteins,
arresting cell proliferation. The mechanism o f action o f this new antitumor compound,
Arglabin, suggests that some o f the plant sesquiterpenes may be useful for anticancer
therapy. Arglabin inhibits famesylation without influencing the geranylgeranylation o f
cellular proteins. The mechanism o f inhibition o f the FTase reaction may be due to
competition between farnesyl pyrophosphate and a phosphoryiated derivative o f Arglabin,
affecting famesyl at the C-terminal cystein residue o f the Ras proteins (Shaikenov et al.,
1998).

Arglabin is registered and approved for usage in clinics in the Republic o f
Kazakhstan as an antitumor medicine. The results o f laboratory and preclinical studies
have supported this usage by showing its high antitumor activity against malignant
tumors. Importantly, the results o f clinical trials found the preparation is non-toxic for the
liver and the kidneys. Also, as a result o f treatment, it has been reported that there was a
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definitive change in the cancerous activities o f hepatocellular cancer and tumors o f the
lungs, breast and ovaries. The patients with liver cancer exhibited rapid reduction in the
size o f tumors. There was general overall improvement o f patient’s condition and
biochemical indices, blood tests, and immune status all improved. The tumors were
slightly reduced in size and then stopped growing. The ovarian cancer patients reported
no accumulation o f ascetic fluid, and tumors were reduced by 30-40% o f their original
size prior to treatment. The preparation had no suppressive effect on hematopoiesis, no
side effects, and appeared to normalize the functions o f the immune system. Also, this
drug did not affect the arterial pressure or other important functions o f cardiovascular
system (Institute o f phytochemistry catalog,

2 0 0 0

).

Arglabin is a colorless crystalline compound isolated from A. glabella,
chromatographically purified, and then recrystallized. In general, this compound is not
water soluble and does not exhibit potent cytotoxicity. To overcome these limitations, the
compound has been modified to render it water-soluble through the addition o f a
dimethylaminohydrochloride group to the C 13 carbohydride moiety, yielding ArglabinDMA (Figure 5). This renders it more effective against tumors at lower concentration.
Arglabin-DMA is phosphoryiated intracellularly. This complex inhibits the famesylation
o f Ras protein by competing with famesyl diphosphate and inhibits cell proliferation o f a
variety o f tumor types (Shaikenov et al., 2001).

The mutation o f ras genes may affect alternative mechanisms o f activation in
tumor cells. The screening o f natural compounds and the design o f chemical molecules
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therefore target the posttranslational modification o f the Ras protein. Some o f these
compounds inhibit the enzyme FTase which is required for Ras to associate with the
plasma membrane (Ouintero et al., 1999). Arglabin, as a biosynthetic derivative o f the
famesyl pyrophosphate, has a similar chemical structure to the famesyl moiety o f Ras
proteins. Arglabin inhibition o f cell growth may be mediated by its phosphoryiated
metabolites in the cells. The action mechanism o f the new antitumor compound, Arglabin,
suggests that some of the plant sesquiterpenes may be useful for anticancer therapy
(Shaikenov, 1997; Shaikenov et al., 1998).

3. APOPTOSIS

Birth and death are the two extremes o f life. A balance between birth and death
regulates cell numbers, relating proliferation, growth arrest, and cell death. A single
ovum after fertilization (zygote) is capable o f dividing and giving rise to a fully grown
individual whose normal somatic cells are programmed to die after aging (i.e.
programmed cell death (PCD) or apoptosis). Normal somatic cells are programmed to die
(or undergo apoptosis); on the other hand, cancer cells program themselves to survive
(Michaelson, 1991; Vermes and Haanen, 1994).

Cancer cells can be considered as a disturbance in the relative rates o f cell
proliferation and cell death. Cancer cells, whose origins are from a group o f normal
somatic cells, have many characteristics in common with those cells. Somatic cells
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undergo aging and die, however, cancer cells also undergo cellular aging but are able to
survive, sometimes achieving immortality (Michaelson, 1991). Some mutated genes
responsible for production of growth factors and their receptors, misdirected signal
transduction pathways, and many cell-cycle regulatory genes have been implicated in this
process o f cancerous transformation (Hanahan and Weinberg, 2000; Lundberg and
Weinberg, 1999; Nowell, 1990).

Traditionally, more attention has been paid to aspects o f cell proliferation rather
than to cell death. There are two major way in which cells die: necrosis and apoptosis.
Necrosis is a pathological death (an uncontrolled cell death), characterized by cell
swelling, mitochondrial damage, a breakdown o f homeostatic control, cell membrane
lysis, aspecific DNA degradation, and leakage o f cell content, etc. Necrotic cells cause
inflammatory reactions in adjacent tissues. However, apoptosis, physiological death, is a
genetically encoded cell elimination program that controls cell numbers and organ size
(Figure 6 ). Although apoptosis as a form o f cell death has been recognized for a long
time, its relevance to cancer has been appreciated only in recent years. Indeed, cells with
DNA damage, which escape the DNA repair mechanisms, are committed to suicide. This
mechanism attempts to prevent the inheritance o f DNA mutations in the potential
progeny o f sublethally damaged cells. Cells from a wide variety o f malignancies show a
decreased ability to undergo apoptosis in response to physiological stimuli (Nowell,
1990).
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In all self-renewing tissues and cells, reproduction through mitosis is
counterbalanced by cell removal through apoptosis. Cells dying by apoptosis usually
undergo characteristic morphological and biochemical changes. Apoptosis, an orderly
and genetically controlled form o f cell death, concludes with phagocytosis o f cellular
remnants without causing damage such as inflammatory reactions to adjacent tissues.
Apoptotic cells undergo separation from their neighbors by morphological, biological,
and molecular changes. The types o f morphological change consist o f membrane
blebbing, chromatin condensation, nuclear breakdown into micronuclei, and cytolysis
into condensed apoptotic bodies. The types o f biological and molecular changes include
BCL-2/BAX interactions, loss o f mitochondrial membrane potentials, phosphatidylserine
extemalization, DNA denaturation and cleavage (50-300kb) among others. Apoptosis is
an important feature that allows the organism to eliminate DNA-damaged cells, and
prevents survival o f suboptimal cells in tissues which may otherwise lead to the
propagation o f damaged DNA to daughter cells (Hanada et al., 1993; Rechavi et al., 1989;
Vermes and Haanen, 1994).

One o f the first organisms in which suicide genes were identified was
Caenorhabditis elegans, a nematode. Two death genes, ced-3 and ced-4, and an anti
death gene, ced-9, have been identified in C. elegans. In mammalian cells, a cancercausing oncogene, bcl-2, which is an anti-suicide gene similar to ced-9 o f C. elegans, is
23% identical in sequence. Bcl-2 was shown to prevent lymphocytes from committing
suicide and to block apoptosis. Recently, the ced-3 gene o f roundworm, which plays a
role in apoptosis, was shown to have sequence homology with a mammalian gene, “ICE”.
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This gene encodes a cysteine protease involved in the processing o f interleukin-lb and
acts as an interleukin-lb-converting enzyme (ICE) (Stewart, 1994; White, 1993).
Therefore, the C. elegans model has been valuable in the identification o f the proteins
that control apoptosis in human cells (Wickremasighe and Hoffbrand, 1999).

The process o f apoptosis is dependent on the activities o f a family o f proteases
known as caspases (Alnemri et al., 1996). Caspases exist as inactive zymogens in all
animal cells (Nagata, 1997). The activities o f these proteases are governed directly or
indirectly by a variety o f other proteins that either promote or inhibit apoptosis. The final
step o f apoptosis induction, termed ‘execution’, involves proteases o f the ICE family,
which directly causes destruction o f the cell (Martin and Green, 1995). Members o f a
family o f proteases, the cysteine proteases, have an active site with a conserved amino
acid sequence allowing them to cleave proteins following aspartate residues. These
proteases play a direct role in the hydrolytic digestion of the cell. They have been dubbed
caspases (cysteine-dependent aspartate cleaving protease) due to their shared structural
and functional features. Caspase-1 was the first member to be identified as a protease
involved in mammalian apoptosis, due to its homology with CED-3 (White, 1993; Yuan
et al., 1993). To date, ten members o f this family have been identified by structure and
substrate specificity in mammalian models. It is now generally accepted that the proteins
involved in the execution of apoptosis belong to the caspase family. The caspases can be
activated to induce apoptosis under a variety o f conditions which include receptor-ligand
coupled signal transduction, DNA damage, lack o f growth factors, oxidative stress, and
breakage o f cell-cell and cell-matrix interactions.
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When cells undergo apoptosis, they generally follow one o f two major pathways.
Though they share some mechanisms, these two pathways can be separated into an
extrinsic pathway, and an intrinsic pathway. In some cases, extrinsic signals such as
death receptor ligands (cytokines) are the apoptotic stimuli. This is also called the death
receptor pathway. Such a mechanism is best illustrated by the tumor necrosis factor
receptor (TNFR) family members, such as Fas (CD95, specific for the Fas ligand) and
TNFR1 (which binds TNF). Upon its activation, Fas recruits FADD (Fas-associated
death domain) by interaction o f their respective death domains (DDs). Similarly, TRADD
(TNFR 1-associated death domain protein) binds to TNFR1 and connects it to FADD via
interaction between these domains. Subsequently, FADD activates FLICE (FADD-like
ICE, caspase), inducing the apoptotic execution which is the final stage o f apoptosis. The
procaspase recruited by death domain is immediately cleaved to produce the initiation
caspase (caspase 8 ) (Green, 1998; Nagata, 1997). In the second type o f death pathway,
intrinsic signals such as damage caused by radiations and chemicals induce apoptosis in
p53-dependent manner (Bennett, 1999). This is also called the intrinsic pathway or druginduced pathway o f apoptosis. The mitochondria and caspase apoptotic pathways are
intimately connected (Sellers and Fisher, 1999). One o f the proapoptotic factors released
from mitochondria during apoptosis is cytochrome c. In the cytosol, cytochrome c binds
the adapter protein Apaf-1 and, in the presence o f ATP/dATP, it promotes the assembly
o f a multiprotein complex called the apoptosome which, in turn, binds and activates
procaspase-9 (Ferraro et al., 2003). The apoptosome is the executioner o f the intrinsic
pathway.
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The second apoptotic pathway is likely regulated by the Bcl-2 family o f proteins.
The Bcl-2 family consists o f proapoptotic factors such as Bax, Bak, Bcl-Xs, Bid, and Bad,
and antiapoptotic factors such as Bcl-2, Bc1-Xl, and Bcl-W. Proapoptotic Bcl-2 family
members tmaslocate to and alter the permeability o f the mitochondrial membrane. The
proapoptotic factors activate to release cytochrome c. Bcl- 2 and Bc1-Xl however act to
prevent cytochrome c release and thus interfere with this caspase pathway (Green, 1998).
The caspases are influenced by association o f two different factors in Bcl-2 family such
as Bax-Bax homodimer functions in active apoptosis. Also, the process can be opposed
by heterodimerization o f Bax with Bcl-2 (Bax-Bcl-2). This association blocks caspase
activity and therefore allows for cell survival. It has been suggested that the ratio o f Bcl-2
to Bax determines survival or death following an apoptotic stimulus (Hoffman and
Liebermann, 1994; Oltvai et al., 1993; Yang and Korsmeyer, 1996).

Recently, Bid, one o f the Bcl-2 family, was found to be a very important
mechanism for cross-talk between the apoptotic pathways. Inefficient activation o f
caspase - 8 under the extrinsic pathway cleaves Bid, producing a C-terminal fragment.
Activated Bid binds to mitochondria and induces release o f cytochrome c, causing the
formation o f the apoptosome in the intrinsic pathway. The initiation caspases (caspase- 8 ,
-9) activate execution caspases such as caspase-3, - 6 , and -7. These execution caspases
cleave relevant substrates that induce the biochemical and morphologic characteristics of
apoptotic cells (Pruschy et al., 2001) (Figure 7).
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Oncogenes and tumor suppressor genes control the balance between apoptotic
death and antiapoptotic survival signals, which determine whether a cell proliferates or
dies. Changes in products o f oncogene or tumor suppressor genes can be responsible for
initiation of apoptosis (Leblanc et al., 1999). The c-myc oncogene, which is known to be
important for control o f cell proliferation, plays a part in the regulation o f apoptosis. Ras
activation o f PI3K suppresses c-Myc-induced apoptosis through the activation of
PKB/Akt (Kauffmann-Zef et al., 1997). Removal o f activated Ras in tumor cells initiates
apoptosis that is dependent on c-Myc activity. Apoptosis is also initiated by an inhibitor
o f MEK (MAPK/ERK kinase), a kinase downstream o f Ras (Tsuneoka and Mekada,
2000). Ras-mediated signals, that inhibit apoptotic cell death, were shown to act through
PI3-kinase and AKT pathways, both leading to a block o f cytochrome c release from the
mitochondrial outer membrane (Kennedy et al., 1999). The tumor suppressor gene, p53,
has been shown to have dramatic effects on apoptosis. Its gene product, p53, can delay
cell cycle progression before initiation o f DNA replication by arresting this cycle
following DNA damage (Slichenmyer et al., 1993). The putative oncogene bcl-2 is
considered to be an apoptosis suppressor gene. Multiple genetic events are associated
with tumor development. Among those events are the activation o f bcl-2, and the
inactivation o f apoptotic inducers such as p53 and bax (Chiou et al., 1994).

Cell death can also be induced by hormonal signals (prostaglandin E, adenosine)
to the membrane. cAkinase (cAMP-dependent kinase) has been implicated in the nuclear
response to hormonal signals for cell proliferation, differentiation, and apoptosis.
Apoptosis is induced by agents that increase cAMP (eg. cholera toxin, theophyline,
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Isobutylmethylxaminthine) and cAkinase agonists (eg. cAMP analogues). Blocking gene
expression and/or protein synthesis can prevent cAMP-induced apoptosis. ICER
(inducible cAMP early repressor) represses cAMP-induced cell death. This indicates that
cell death was induced by transcriptional activation o f a ‘killer’ gene regulated by a CREcontaining promoter. ICER and Bcl-2 both act as upstream and downstream switches
respectively, and may decide the fate o f the cell (Raghoebier et al., 1991; Rechavi et al.,
1989).

Many chemotherapeutic agents o f diverse origin and different primary target
molecules may induce apoptotic cell death in cancer cells via a convergence o f
intracellular pathways. Thus, the identification o f impediments to this pathway, whether
o f genetic origin (e.g. bcl-2) or by interacting cytokines or factors as yet unknown, are
important in identifying potential causes o f drug resistance in malignant cells (Allen et al.,
1993).

Recent data show that in some cellular models, chemotherapeutic agents induce
apoptosis, an irreversible process which leads to a rapid and complete elimination o f
tumor cells. However, further studies also demonstrated that apoptosis, induced by
anticancer agents, is highly regulated by multiple signaling pathways which are
themselves influenced by oncogenes, protein kinase/phosphatase activities, external
stimuli, and the oxidative balance. Often, they share the same signaling pathways with
cell proliferation and differentiation (Ruchaud and Lanotte, 1997). Therefore, it appears
that cell death commitment is controlled by both external and internal factors which
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interfere with the downstream o f drug-target interactions. The characterization o f these
factors may provide novel targets for modulating drug-activated intracellular signaling
pathways in order to promote apoptosis in drug-resistant cells (Allen et al., 1993; Sellers
and Fisher, 1999).

Two major cellular effects o f FTI are cell cycle effects and induction o f apoptosis.
The FTI-induced apoptosis involves changes in mitochondrial membrane potential and
the release o f cytochrome c. The released cytochrome c activates caspase-9 and caspase-3,
leading to DNA fragmentation. Detection o f FTI-induced apoptosis requires special
conditions, such as exposing cells to low serum conditions to inhibit cells from attaching
to extracellular matrix (Edamatsu et al., 2000; Lebowitz et al., 1997; Suzuki et al., 1998).

4. CELL CYCLE

The cell cycle consists o f four sequential stages. Gi is the first gap phase in which
cells prepare for DNA replication. In this phase, cells monitor both their internal and
external environments to determine whether to divide or to remain in a state o f
quiescence, known as Go. In Go, basic cellular metabolism is depressed in general,
including transcription and transition. Once initiated, the cell progresses from the Gi to S
phase, the period o f DNA synthesis for the reproduction o f the whole genome. Then, the
cell progresses to the G 2 phase, the second gap phase in which cells prepare for mitosis,
before entering into M phase. M phase, or mitosis, is the period o f cell division in which
two identical daughter cells are produced during prophase, prometaphase, metaphase,
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anaphase, and telophase. Cells can exit the cell cycle to settle into the Go phase in
response to the deprivation o f nutrients and growth factor stimulation (Brooks and La
Thangue, 1999; Owa et al., 2001).

As cells enter the cycle from Go/Gi,one or more D-type cyclins (D l, D2, and D3)
are expressed as part o f the delayed early response to mitogen stimulation. Progression
through the Gi phase initially depends on holoenzymes composed o f one or more o f the
D-type cyclins (D l, D2, and/or D3) in association with cyclin-dependent kinases (CDKs),
CDK 4 or CDK 6 . The CDKs are protein complexes that are composed o f a regulatory
cyclin subunit and a catalytic partner. This is followed by activation o f cyclin E-CDK 2
complex as cells approach the Gi/S transition. Together, cyclin E and CDK 2 act to
hyperphosphorylate retinoblastoma protein (pRb), which then releases the elongation
factor E2F that activates DNA polymerase. This step, termed the restriction point,
represents the point o f no return; cell commitment to undergo DNA synthesis (S phase)
and mitosis is inevitable. In the S/G 2 transition and G 2 phase, cyclin A binds CDK 2 and
CDC 2, giving two distinct cyclin A kinase activities, one appearing in S phase, the other
in G 2 (Pagano et al., 1992). The G 2 /M transition is mediated by activation o f the cyclin
B/CDC 2 kinase complex (Figure 8 ). At each phase o f cell cycle, the scheduled activity
o f the CDKs is controlled by their association with cyclins and the CDK inhibitors
(CKIs). CKI molecules are categorized into two separate families: 7) INK 4 family
(p l 6 INK4a, p l5 INK4b, p l 8 INIC4c, and p l9 INK4d) specifically inhibit the catalytic subunits o f
CDK 4 and CDK 6 ; and 2) Cip/Kip family (p21Cipl, p27Kipl, and p57Kip2) inhibit the
activities o f cyclin D-, E-, and A-dependent kinases (Ammit and Panettieri, 2001; Sherr
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Figure 8 The cell cycle. The normal cell division cycle is sub-divided into four distinct
phases: two gap phase (GI and G2), S phase and M phase. CDK; cycling-dependent
kinase, CDC 2; cell-division cycle, one o f the CDKs (Brooks and La Thangue, 1999).
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and Roberts, 1999). Each phase o f the cycle is under the control o f specific positive and
negative regulators that either promote or arrest cell-cycle progression depending on their
relative levels o f expression (Brooks and La Thangue, 1999; Shapiro and Harper, 1999).

Proliferative disorders such as cancers are recognized as diseases o f the cell cycle.
The disorders are found in genetic alterations affecting proteins that control cell cycle
progression. The mechanisms that normally function to restrain cell division are defective,
while those that promote division become more active. The genes responsible for these
changes in growth potential are generally named tumor suppressors and oncogenes,
respectively (Brooks and La Thangue, 1999; Wang et al., 1996).

Ras proteins are encoded from the proto-oncogene ras, and are involved in cell
signaling and regulation of cell proliferation. Activated Ras interacts with a diverse
spectrum o f effectors, initiating a multitude o f cytoplasmic signaling cascades. Recent
studies have begun to establish the links between Ras signaling pathways and cell cycle
regulatory proteins. The mechanism by which aberrant Ras and Rho GTPase activation
promotes oncogenesis clearly involves a deregulation o f cell cycle progression. Much is
now known regarding how Ras and Rho signaling can control both positive and negative
regulators to facilitate an exit from Go, progression through Gi, and initiation o f DNA
synthesis (Bar-Sagi and Hall, 2000). R af signal, activated by Ras, can induce cyclin D l
expression, allowing cyclin D l to complex with Cdk4 and Cdk6 and phosphorylate Rb to
affect the GI to S transition. Rho activates CDK 2 and also inhibits p21Cipl and p27K'pl to
induce cyclin D l and stimulate the GI to S transition. Rho represses p21Cipl expression to
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block p21Cipl induction by Ras and to allow Ras induced progression from GI to S
(Liberto et al., 2002). Also, Rac, one o f the Rho family members appears to induce cyclin
D l expression and induce the GI to S transition primarily through activation o f NF-kB to
activate the cyclin D l promoter. The cooperative action o f Ras, Rac and Rho to induce
cyclin D l expression is a key component o f oncogenic transformation (Chang et al.,
2003; Pruitt and Der, 2001).

Recent excitement in cancer research concerns the development o f a new
generation o f antitumor drugs. These drugs are designed to target molecular events
specific to cancer cells, including FTIs (famesyl transferase inhibitors). FTIs have been
developed in an attempt to inhibit membrane association o f Ras. While it is demonstrated
that FTIs are effective in reverting phenotypes due to H-ras activation, a number o f
reports suggested that there are targets other than Ras that are critical for the FTI effects.
Studies on protein famesylation define the effects o f FTIs on cancer cells with the aim of
gaining insight into the involvement o f famesylated proteins other than Ras on FTIs.
These include members o f the Ras superfamily G-proteins (Foster et al., 1996; Lebowitz
et al., 1997; Murphy et al., 1996). One o f two major effects o f FTI is the ability to cause
changes in cell cycle progression (Jiang et al., 2001; Tamanoi et al., 2001). The cell cycle
effect involves enrichment o f either Go/Gi phase cells or G 2 /M phase. Characterization of
the FTI-induced G 0 /G 1 enrichment led to the findings that FTI affects the expression and
modification o f a number o f cell cycle related proteins. With some cell lines, G 2 /M
enrichment was detected after the treatment with FTI (Jiang et al., 2001).
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5. PURPOSE OF THIS STUDY

Many chemotherapeutic agents induce cell death in tumor cells via a convergence
o f intracellular pathways, which lead to apoptosis. After chemotherapy, the balance
between the relative rates o f cell proliferation and cell death is related to the regulation o f
apoptosis or the cell cycle. In previous studies, the major cellular effects o f FTase
inhibitors (FTIs) were cell cycle effects or induction o f apoptosis. Arglabin-DMA has
been shown to be a potent inhibitor o f tumor growth. It may inhibit FTase as the
chemotherapeutic target. However, the mechanisms by which Arglabin-DMA inhibits
tumor growth in vivo and in vitro are still relatively unknown. To elucidate this
mechanism, we hypothesize that Arglabin-DMA has major cellular effects similar to
those o f other FTIs to inhibit tumor growth.

The present study addresses the effects o f Arglabin-DMA in vitro, using a
cultured cell model to confirm or refute its proposed role as a Ras-dependent FTI. To
determine the mechanism by which this drug inhibits tumor growth, the effects o f
Arglabin-DMA are examined in human colon tumor cells. Experimentation is divided
into three specific aims: In the first specific aim, we re-examine the ability o f ArglabinDMA to inhibit Ras activity in vitro. The second examines whether Arglabin-DMA
inhibits cancer growth in an apoptosis-dependent manner. Finally, we determine that
Arglabin-DMA induces cell cycle arrest in human colon tumor cell lines.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

37
5.1. Reexamination o f the ability of Arglabin-DMA to inhibit farnesylation on the
Ras protein in vitro

Viability assays are principally used to enumerate the proportion o f living and
dead cells in a population. Trypan blue is generally used for the viability assay. The
reactivity o f trypan blue is based on the fact that the chromopore is negatively charged
and does not enter the cell unless the membrane is damaged. This stain is actively
extruded from viable cells, but readily enters and stains dead cells. Using viability assays,
the viable population percentage between groups, which have been exposed for varying
times or concentrations of the drug, is compared. These comparisons are used to
determine the effectiveness o f the drug action.

In today's pharmaceutical industry, most o f the new anticancer drug candidates
fail clinical trials due to their toxicity, even though they significantly inhibit tumor cell
growth rate. These high failure rates may be reduced if potential drugs are screened for
toxicity earlier in the drug discovery process. Evaluation o f toxic effects o f potential
drugs is cost effective in an in vitro system using cultured cell lines or primary cells. Also,
cytotoxicity studies are used to predict drug metabolism pathways in humans. To
compare the effects o f Arglabin-DMA in a normal human cell line and colon tumor cell
lines for toxicity, several positive controls (5-Fluorouracil, Lovastatin, or Taxol) were
used.

Previous studies showed that Arglabin-DMA inhibits polyprenylation o f the
cellular proteins, presumably because plant sesquiterpenes function as polyprenols o f

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

38
cellular proteins. Arglabin can inhibit famesylation without influencing
geranylgeranylation (Shaikenov et al., 1998). We attempted to reconfirm that ArglabinDMA inhibits polyprenylation and the formation o f isoprenoids (famesyl pyrophosphate
and geranylgeranyl pyrophosphate) which are byproducts o f cholesterol synthesis.

5.2. Test whether Arglabin-DMA inhibits cancer cell growth in an apoptosisdependent manner

We examine a broad and chronologically characteristic pattern o f morphological,
biochemical and molecular changes o f apoptosis to determine whether Arglabin-DMA
activates apoptosis in human colon tumor cells or not. At the biochemical level of
apoptosis, double-strand cleavages o f genomic DNA are found by conventional agarose
gel electrophoresis and are also detected by the TUNEL assay in our experiments.
Differences in the permeability o f the cell membranes of living, dead, and apoptotic cells,
are used to identify apoptotic cells using two DNA dyes, acridine orange (AO) and
ethidium bromide (EB). The fine architecture o f the cell membrane changes in the initial
phase o f apoptosis. This shift in the architecture o f the plasma membrane involves the
redistribution o f the various phospholipid species between the two leaflets o f the
membrane. We can detect membrane conversion in apoptotic cells through the use o f
Annexin V. Finally, alterations o f the plasma membrane in apoptotic cells lead to the
accumulation within the cell o f a detectable dye.
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5.3. Testing whether Arglabin-DMA induces cell cycle arrest in human colon tumor
cell lines

In the analysis o f the mechanism o f Arglabin-DMA using flow cytometry, the
relationship o f Arglabin-DMA and the cell cycle is studied in colon tumor cells. Once
cells are stained with propidium iodide (PI) as the DNA fluorochromes, they are analyzed
by flow cytometery. Where the relative content o f DNA indicates the distribution o f a
population of cells throughout the cell cycle.

The aim o f this last study is to compare the changes o f the cell cycle after
exposure to Arglabin-DMA. Studies using increased concentrations o f Arglabin-DMA,
followed by examination o f cells using flow cytometry, are capable o f showing the drug’s
concentration correlation with the inhibition o f cell progression. Also, DNA content
frequency histograms may reveal fractional DNA content, represented by the sub-diploid
(<2n: sub-Gi) peak. In late apoptotic cells, DNA is degraded to such an extent that it
becomes extracted during the routine procedure o f cell staining. This approach is
currently the most frequently used in flow cytometry to identify and quantify apoptotic
cells (Nicoletti et al., 1991).
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MATERIALS AND METHODS

1. HUMAN CELL LINES

We investigated the effects o f Arglabin-DMA on two human colon cancer cell
lines, each having different Ras and p53 status (HCT 116 and HT-29). HCT 116, derived
from a colon carcinoma, contains a mutation in codon 13 o f the K-ras protooncogene and
wild-type p53. HT-29, derived from a colon adenocarcinoma, has a mutation in codon
237 o f the p53 and a wild-type ras. The normal cell line (Hs 27), used as a control for
examining cytotoxicity, is a fibroblast. All cell lines were obtained from American Tissue
Culture Collection (ATCC, Rockville, MD. USA).

2. DRUG EXPOSURE

Arglabin, like other sesquiterpenes, is biosynthetically derived from famesyl
diphosphate by cyclization, rearrangements and oxidation. The water soluble form o f
Arglabin is Arglabin-dimethylaminohydrochloride (Arglabin-DMA; Figure 2). Powdered
Arglabin-DMA was obtained from the Institute o f Phytochemistry, Republic o f
Kazakhstan. It was dissolved with distilled water and presented at various final
concentrations (15.25, 30.50, and/or 45.75 pM).
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5-Fluorouracil, Lovastatin, Mynumycin A, or Taxol were used as positive
controls in several experiments. They were obtained from Sigma (St. Louis, MO. USA).
5-Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting
thymidylate synthetase. It was dissolved in DMSO and administrated at 19.22 pM (Nita
et al., 1998). Lovastatin (Mevinolin) is a potent inhibitor o f HMG-CoA reductase, the
rate-limiting enzyme in cholesterol biosynthesis. Lovastatin was dissolved in methanol
and administrated at 10 pM (Agarwal et al, 1999; Agarwal et al, 2002). Manumycin A is
a FTI (famesyltmasferase inhibitor) in that it is FPP (famesyl pyrophosphate) analog. It
was dissolved in methanol and administrated at 20 pM (Di Paolo et al, 2000). Taxol
(Paclixel) is an anti-tumor agent which binds to the N-terminal region o f (5-tubulin. It was
dissolved in distilled water and administrated at 58 nM (Banerjee et al., 1997). All drugs
were stored at over -20°C and solutions were prepared fresh for each experiment.

3. INITIATION AND MAINTENANCE OF HUMAN CELL LINES

Two colon tumor cell lines and one fibroblast line were stored at -155°C,
according to the instructions o f ATCC for use. Complete media for HCT 116 and HT-29
was prepared using McCoy 5A medium (Sigma, St. Louis, MO. USA). Complete media
for Hs27 was prepared with Dubecco’s modified Eagle’s medium (Sigma, St. Louis, MO.
USA), each containing 10% fetal bovine serum (GIBCO BRL, Life Technologies,
Gaithersburg, MD. USA), 200 mM Glutamine, 50 units/ml penicillin, and 50 mg ml"1
streptomycin (Sigma, St. Louis, MO. USA). Cells were thawed and placed in 25 cm
culture flasks (T-25) (Coming, Coming, NY. USA) in volumes o f 5ml o f complete media.
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Cells were allowed to adhere to flasks, and the flasks were placed in a 37°C incubator
with 95% air, 5% CO 2 humidified atmosphere. Cells were fed every 2 days with complete
media after old media were discarded. The primary cultures were allowed to grow to
subconfluence, trypsinized, and passed into 75 cm culture flasks (T-75) (Coming,
Coming, NY. USA). Depending on the cell density, cells in a given flask were
subcultured into two or three flasks before reaching confluence.

Under these conditions, the population doubling time o f HCT 116 was about 24
hours, that o f HT-29 was about 30 hours, and that o f Hs27 was about 48 hours. Cultures
were regularly examined under the microscope for contamination and/or confluence; if
the culture was contaminated, we added 1 to 2 ml o f bleach and disposed o f cultures in an
appropriate biohazard container. If the cells grew to confluence, they were split. Cultures
were found to be free o f Mycoplasma contamination procedure. All experiments involved
cells that were passaged more than 30 times. All procedures were performed under a
sterile hood utilizing sterile techniques.

4. TRYPSINIZATION AND CELL PASSAGE

Cultures were passaged and harvested using 0.05% trypsin-EDTA (Sigma, St.
Louis, MO. USA) to detach the cells. The cells grown to confluence were prepared to be
split. The media from flasks was removed and discarded in bleach. The flasks were rinsed
with 3 ml o f trypsin-EDTA to remove residual media. Two ml o f trypsin-EDTA in T-25
flasks, or 4 ml o f trypsin-EDTA in T-75 flasks were added. The flasks were placed in the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

43
incubator at 37°C. Trypsinization was periodically observed under the light microscope,
as various cell types detach at different rates (trypsinization is typically complete within 3
to 10 minutes). When most o f the cells had become “rounded” (i.e., when the trypsin had
disrupted the cells’ protein connection to the flask surface), the flasks were tapped gently
on each side to dislodge the attached cells into suspension. Each flask was neutralized
with complete media, using the same as the amount o f trypsin-EDTA. The cells and
media were triturated to obtain a homogenous suspension. The cell suspension o f colon
tumor cell lines was aliquoted in 1 ml volumes into new sterile T-25 flasks or aliquoted in
3 ml volumes into new sterile T-75 flasks. The cell suspension o f Hs 27 (normal cell line)
was aliquoted in 2 ml volumes into new sterile T-25 flasks (5 ml total volume) or
aliquoted 6 ml volumes in to new sterile T-75 flasks (15 ml final volume).

5. CELL COUNTING AND CELL VIABILITY

Cells were plated in T-25 at a density o f 2 * 104 cells per cm2. After incubation
for 24 hours, old media were discarded. This step was done to insure that more precise
data would be obtained, due to the fact that Arglabin-DMA induces cell rounding and
detachment. Complete media containing Arglabin-DMA were added to the flasks at
various final concentrations (0, 15.25, 30.50, and 45.75 pM). 5-Fluorouracil (19.22 pM);
Lovastatin (10 pM); or Taxol (58 nM) was used, separately as positive controls, and
compared to the growth inhibition rate o f Arglabin-DMA. Detached and attached cells in
control and drug exposure samples were collected by trypsinization at different times (24,
48, and 72 hours) o f incubation. As in the previously described trypsinization, the cells
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and media were triturated to a homogenous suspension. 300 pi o f the suspension was
diluted 1:1 with pipette into 300 pi o f 0.4% trypan blue solution (Sigma, St. Louis, MO.
USA) into a disposable culture tube. The diluted suspension was mixed to the disposable
culture tube containing the cell suspension. One drop from the disposable culture tube
was pipetted into the hemacytometer and allowed to stand for 5 minutes.

The viable cells appear clear and round with no blue-colored dye; the blue-dyed,
non-viable cells were counted in the four comer square chambers o f the grid o f a
hemacytometer. Use o f a hemacytometer is critical for obtaining an accurate count of
cells. The cell count was calculated using the equation: cells/ml = (n) x 104, where: n =
the average cell count per square o f the four com er square chamber counted. We
determined the total number o f cells in the total suspension volume. The percent viability
o f cells in culture was calculated. The cellular morphologies o f human cell lines in
various assays were examined under Olympus phase light microscope (Tokyo, Japan) at
100 x magnification. Light photomicrographs (ISO 200 and 400) were taken with an
Olympus camera (Tokyo, Japan).

6. ADD-BACK EXPERIMENTS

To evaluate the cellular mechanisms involved in Arglabin-DMA growth
inhibition, add-back experiments were performed, adding intermediates (farnesyl
pyrophosphate (FPP), or geranylgeranyl pyrophosphate (GGPP)) in cholesterol
biosynthesis which belong to a class o f molecules called isoprenoids (Holstein et al.,
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2002). Isoprenoids are attached to several cellular proteins, including G proteins, by a
posttranslational modification termed isoprenylation (Agarwal et al., 1999). Lovastatin,
which served as a positive control, induces morphological changes (cell-rounding and
detachment) similar to Arglabin-DMA-induced cell-rounding and detachment. It is an
HMG-CoA reductase inhibitor. Inhibition o f HMG-CoA reductase inhibits the formation
o f isoprenoids and thereby impairs the post-translational processing o f Ras and Rasrelated proteins (Rap la, RhoA, and RhoB). Isoprenylation o f target proteins, like the
GTP-binding protein Ras, is essential for their membrane localization (Agarwal et al.,
2002). Manumycin A, a second positive control, is a natural product derived from the
bacterium Streptomyces, and is a FPP analog similar to Arglabin-DMA. It acts by the
specific inhibition o f the FTase and exerts antiproliferative effects on human tumor cells
which harbor a mutated K-ras gene (Di Paolo et al., 2000).

HCT 116 or HT-29 cells were seeded at 2 x 104 cells per cm2 on T-25 flask,
permitted to attach and grow for 24 hours. We discarded the old media and divided the
cells into two groups after adding 30 pM Lovastatin, 61 pM Arglabin-DMA, or 20 pM
Manumycin A, dissolved in fresh, complete media. 100 pM Famesyl pyrophosphate
(Sigma, St. Louis, MO. USA), or 10 pM geranylgeranyl pyrophosphate (Sigma, St. Louis,
MO. USA) was then added. The samples were incubated for 3 days and photographs
were taken after 1 and 3 days incubation for comparing the morphological appearances o f
the samples. 1 x 106 cells o f each sample were collected. We followed the experimental
procedures for cell viability for counting cells and also checked the change in the number
o f the floating cells, related to apoptotic cells. Higher doses o f Lovastatin (30 pM),
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Manumycin A (20 pM), and Arglabin-DMA (61 pM) were used in these experiments to
clarify the inhibiting potential effect o f these drugs.

7. ANNEXIN V ASSAY

HCT 116 or HT-29 cells were seeded at 2 xlO4 cells per cm2 in T-25 flask and
incubated for 24 hours. We discarded the old media and added three final concentrations
o f Arglabin-DMA (0, 15.25, 30.50 and 45.75 pM) dissolved in fresh, complete media.
After three days o f incubation, each cell line was split into three separate groups (control,
attached in Arglabin-DMA treatment, and floating in Arglabin-DMA treatment). The
following steps were followed using the ApoAlert Annexin V protocol (Clontech, Palo
Alto, CA. USA). At each time point, 1 xlO6 cells o f each group were collected. The cells
were rinsed and resuspended with 1 x Binding Buffer (0.1 M HEPES, pH 7.4; 1.4 M
NaCl; 25 mM CaCh). 10 pi PI and 5 pi EGFP-labeled recombinant human Annexin V
was added. For analyzing cells, the cell suspensions were incubated on a glass slide at
room temperature for 5-15 minutes in the dark. Slides were covered with a glass
coverslip and observed under an Olympus fluorescence microscope (Tokyo, Japan), at a
magnification o f 200 x, using a filter set for acridine orange. Light photomicrographs
(ISO 100) were taken with a Nikon camera (Tokyo, Japan) using 640T Tungsten chrome
color film of Imation (Oakdale, MN. USA).
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8. APOPTOSIS DYE-UPTAKE ASSAY

A second technique to detect alterations o f the plasma membrane is the
Apopercentage assay (Biocolor, Newtownabbey, Northern Ireland). During apoptosis,
cells undergo the onset o f the ‘flip-flop’ alteration to the cell membrane, causing
translocation o f phosphatidylserine to the exterior surface o f the cell membrane. The
Apopercentage Dye enters the cell following this event, and dye uptake continues until
‘blebbing’ is induced. At this stage, no further dye can enter the cell. Once in cells,
Apopercentage does not escape (Wilson and Elliott, 2001).

Cells o f each cell line were seeded at 2 x 104 cells per cm2 in T-25 flask and
allowed to attach overnight. The medium was replaced with fresh media or fresh media
containing 30.50 pM Arglabin. After exposure o f these cells to Arglabin-DMA, two cell
lines o f different ras status, HCT 116 and HT-29, underwent the morphological changes
causing them to round up and become detached from the substrate. In determining cell
viability, 80-95% floating cells were live cells that did not stain with trypan-blue. For
examining floating cells that were morphologically affected by Arglabin-DMA, we
collected and examined cells divided into two groups (floating or attached groups) in
each o f the colon cell lines after three days incubation. 2 x 105 attached cells or floating
cells were collected and counted. Harvested cells were given two washes with PBS. 100
pi aliquots o f complete culture medium containing Apopercentage Dye Label were added
and samples were incubated for 1 hour at 37°C. Cells in each group were collected and
resuspended in 1 ml o f serum-free medium. The cellular morphologies in the
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Apopercentage assay were examined. Normal cells, which appear clear, are round and
exclude the dye; the apoptotic cells stained purple-red were counted in a hemacytometer
under an Olympus phase light microscope (Tokyo, Japan) at a magnification o f 100 x.
Light photomicrographs (ISO 200 and 400) were taken with an Olympus camera (Tokyo,
Japan). Total apoptotic and normal cell numbers and the percent apoptotic cells were
calculated.

9. IDENTIFICATION OF DYING CELLS BY APOPTOTIC NUCLEAR
MORPHOLOGY

Detection o f apoptotic cells in this experiment is based on differences in the
permeability o f the cell membranes o f living, dead, and apoptotic cells. Two DNA dyes,
acridine orange (AO; Sigma, St. Louis, MO. USA) and ethidium bromide (EB; Sigma, St.
Louis, MO. USA), were used to find apoptotic cells.

HCT 116 or HT-29 cells were inoculated into 25 ml flasks with a viable cell
density o f 2 * 104 cells/cm2. After incubation for 24 hours, old medium was discarded,
and fresh complete media with or without 30.50 pM Arglabin-DMA was added. After
samples were incubated for three days, cells were divided to in three groups (control,
attaching in Arglabin-DMA treatment, and floating in Arglabin-DMA treatment) and
trypsinized for different times for each group. Cell counts were made to determine cell
viability and cytotoxicity.
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After counting, cells were given two washes with 1 x phosphate buffered saline
(PBS) (0.14 M NaCl; 3 mM KC1; 10 mM Na2HPO; 2 mM KH2P 0 4, pH 7.2). Twenty-five
microliters o f the cell suspension were mixed with 1 pi of the dye mixture containing 100
pg/ml AO and 100 pg/ml EB in PBS (pH 7.2). EB, as a fluorescent DNA-binding dye, is
taken up by dying cells only. Metachromatic dye AO is taken up by both live and dead
cells. But apoptotic cells can be distinguished by their different morphologies (Reed,
2000). After staining, cells were mounted on a hemacytometer. Cells were observed
under an Olympus fluorescence microscope (Tokyo, Japan), at a magnification o f 200 x,
using a filter set for AO and 640T Tungsten chrome color slide film o f Imation (Oakdale,
MN USA). Light photomicrographs (ISO 100) were taken with a Nikon camera (Tokyo,
Japan).

The status o f cells was identified by counting the number o f cells exhibiting one
o f five staining patterns: Stage one is bright green chromatin with organized cell
structure-viable cells with normal nuclei. Stage two is bright green chromatin that is
highly condensed-viable cells with apoptotic nucleic in an early phase o f apoptosis. Stage
three is bright orange chromatin that is highly condensed-nonviable cells with apoptotic
nuclei in a late phase o f apoptosis. Stage four is bright orange chromatin that is
fragmented-nonviable cells with apoptotic nuclei in the late phase o f apoptosis. Stage five
is red-dead cells (Reed, 2000).
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10. TUNEL ASSAY

The TUNEL (terminal deoxynucleotidyl transferase-(TdT)-mediated dUTP nick
end labeling) assay was carried out using the Apoptosis Detection Kits protocol (R&D
Systems, Minneapolis, MN. USA). The assay detects biotinylated nucleotides
incorporated onto the free 3’-hydroxyl residues o f DNA fragments, added by Terminal
deoxynucleotidyl transferase (TdT). Also, it inserts a deoxynucleotide-triphosphate,
dNTP, that has a chromophore attached. The use o f this assay results in intense brown
staining o f the nuclei o f apoptotic cells. Since necrotic cells may also contain DNA
fragments that can incorporate label, the identification o f apoptotic cells can be visualized
on a histological section by light microscopy (Reed, 2000). In this assay, attached cells
(HCT 116 and HT-29) were exposed to Arglabin-DMA, and then monitored by the
TUNEL assay to test the occurrence o f apoptotic events.

Sample preparation: Microscope slides and glass coverslips were sterilized by
autoclaving for 20-30 minutes with or without pretreatment with poly-L-lysine or
collagen to assist in cell adhesion. The sterile slides were transferred into a tissue culture
dish. 2 x 104 cells/cm2 o f HCT 116 or HT-29 were seeded in the tissue culture dish and
allowed to attach overnight. The media were replaced with fresh media or fresh media
containing 30.50 pM Arglabin. After 72 hours o f incubation, the media were removed
from the dish and the slides with adherent cells were carefully rinsed with 1 * PBS (0.14
M NaCl; 3 mM KC1; 10 mM NaiHPO; 2 mM KH2PO4, pH 7.2). The rinsed cells were

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

51
fixed by adding 3.7 % formaldehyde solution (1 x PBS with 37% Formaldehyde) for 10
minutes at 18-24 °C and then washed with 1 x PBS.

Labeling and detection: Each sample was permeabilized by incubation with 50 pi
Proteinase K Working Solution (1 pi Proteinase K; 50 pi sterile water). The slides were
incubated in a humidity chamber for 30 min at 18-24 °C and washed twice. To prepare
the Nuclease-generated Positive Control using TACS-Nuclease, 50 pi o f TACS-Nuclease
Working Solution (1 pi TACS-Nuclease with 50 pi TACS-Nuclease Buffer) was pipetted
onto a no drug sample. A coverslip was placed, and the slide incubated for 10 minutes in
a humidity chamber. The other samples were covered with TACS Nuclease buffer during
preparation o f the Positive Control. The samples were immersed in Quenching Solution
(30% H 2 O 2 with 45 ml Methanol) for 5 minutes, quenching potential high levels o f
endogenous peroxidase, and then the samples were washed for 1 minute to remove H 2 O 2
solution. The samples were immersed in 1 x TdT (Terminal deoxynucleotidyl
Transferase) Labeling Buffer (10 x Labeling Buffer) for 5 minutes. The entire specimen
was covered with 50 pi o f Labeling Reaction Mix (1 pi TdT dNTP Mix; 1 pi 50 x Mn2+;
1 pi TdT enzyme; 50 pi 1 x TdT Labeling Buffer). To prepare an unlabeled Sample
Control, one sample was treated with Labeling Reaction Mix from which the TdT
enzyme had been omitted. All o f the samples were placed in a humidity chamber in a
37°C incubator for 1 hour. The reaction was stopped by immersing the samples in 1 x
TdT Stop Buffer for 5 minutes. The samples were washed twice with 1 x PBS for 5
minutes per wash and dried. 50 pi o f Streptavidin-HRP Working Solution (1 pi
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Streptavidin-HRP; 50 pi o f 1 x PBS) were pipetted onto each sample to cover the entire
specimen. The samples were incubated for 10 minutes and washed twice, 2 minutes per
wash with 1 x PBS. The samples were immersed in DAB Working Solution (30% H 2 O 2 ;
250 pi diaminobenzidine; 50 pi 1 * PBS) as background staining may occur. The
samples were washed twice in tap water for 2 minutes each wash.

Counterstaining: The samples were immersed in 1% Methyl Green Counterstain
for 1 minute and washed sequentially by dipping in each o f the following solutions:
deionized water (2 changes, ten times each); 95% ethanol (2 changes, ten times each);
100 % ethanol (2 changes, ten times each); xylenes (2 changes, ten times each). Each
sample was pipetted with 50 pi o f mounting medium (Permount, Williston, VT, USA)
and grown on glass coverslips. The cellular morphologies o f human cell lines in various
assays were examined under Olympus phase light microscope (Tokyo, Japan) at 100 x or
200 x magnification. Light photomicrographs (ISO 200 and 400) were taken with an
Olympus camera (Tokyo, Japan).

11. ANALYSIS OF DNA FRAGMENTATION

In apoptotic cells, DNA fragmentation is regular, in contrast to the random DNA
degradation that occurs in necrotic cells, in that it involves the generation o f large DNA
fragments. Apoptotic cells reflect double-strand cleavage o f linker DNA between
nucleosomes. Large DNA fragments were found by conventional agarose gel
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electrophoresis, followed by the appearance o f a ladder of low molecular weight
fragments that are multiphases o f ~180bp (Vermes and Haanen, 1994; Reed, 2000).

In previous studies o f cell viability, exposure o f cells to Arglabin-DMA caused
them to round up and become detached from the substrate, suggesting that this compound
may induce cells to undergo apoptosis. Therefore, three groups (control, attached in
Arglabin-DMA treatment, and floating in Arglabin-DMA treatment) were separately
collected. In order to detect the induction o f apoptosis, DNA fragmentation, reflecting the
endonuclease activity characteristic o f apoptosis, was detected with DNA samples
extracted from the Arglabin-DMA treated cells at one or three days.

2 x 104 cells/cm2 per cell line (HCT 116 or HT-29) were seeded in T-75 flasks
and allowed to attach overnight. The media were replaced with fresh media, or fresh
media containing 30.50 pM Arglabin-DMA, 10 pM Lovastatin or 58 nM Taxol. After 1
or 3 days o f incubation, cells were collected in three groups (control, attached in
Arglabin-DMA treatment, and unattached in Arglabin-DMA treatment), and counted.
Harvested cells (over 3 x 106 cells) were lysed and transferred to centrifuge tubes. After
centrifuging at 600g for 5 minutes, the supernatant was incubated with 18 pg/ml
proteinase K overnight at 50°C. The samples were centrifuged at 2000g for 5 minutes,
and 100 pi o f sodium perchlorate was added. The upper layer was extracted in 150 pi of
Nucleon resin (Amersham Life Science, Buckinghamshire, UK). DNA was precipitated
with 2 volumes of cold absolute ethanol. Precipitates were washed twice with 1 ml cold
70% ethanol and re-centrifuged at top speed (minimum 4000g). The pellet was air dried
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for 10 min. The DNA was dissolved in 100

jj.1

TE buffer (10 mM Tris HC1;

1

mM EDTA,

pH 8.0). After treatment with 2 pg/ml RNase solution for 30 minutes at 37°C, the DNA
sample was diluted, 2 pi into 1000 pi distilled water, and the DNA samples were placed
in a quartz cuvette in order to read the optical density (OD). The concentration o f DNA
was read by measuring the absorbance o f a sample at 260nm (A 2 6 0 ) on a UV-visible
recording spectrophotometer (Shimadaza, Kyoto, Japan). A 1.8% agarose gel was made
with 0.6 g agarose containing ethidium bromide (0.5 pg m l'1) in 40 ml TBE buffer (89
mM Tris base; 89 mM Boric acid; 2 mM EDTA, pH 8.2). 10 pg DNA samples in 1/5
DNA volume o f 6 x loading buffer (0.25% bromophenol blue; 0.25% xylene cyanol;
30% glycerol) were loaded on the agarose gel and electrophoresed at 100 volts until the
dye marker had migrated almost to be bottom o f the gel. 1 kb plus DNA ladder (Life
Technologies, Rockville, MD, USA) was used as the molecular weight DNA marker.
After electrophoresis, the gel was visualized under UV light, and photographed using a
Kodak DC 120 zoom digital camera (Eastman Kodak Company, Rochester, NY. USA).

12. FLOW CYTOMETRY ANALYSIS OF CELL CYCLE

The method is based on elution o f low-molecular weight DNA from the ethanolfixed cells, which is followed by cell staining with propidium iodide (PI; Sigma, St.
Louis, MO. USA) as the DNA fluorochrome. PI binds to the major groove o f double
stranded DNA after permeabilization o f cells, which produces a highly fluorescent adduct
that can be excited at 488 nm with a broad emission centered around 600 nm. Since PI
can also bind to double-stranded RNA, it is necessary to treat the cells with RNase for
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optimal DNA resolution (Banerjee et al., 1997; Krishan, 1975). The relative content of
DNA indicates the distribution o f a population o f cells throughout the cell cycle. For
cycling cells, cells in the Go/Gi phases o f the cell cycle have a diploid DNA content (2n).
Cells within the G 2 /M phases have a DNA content o f 4n, while S phase has a DNA
content greater than 2n and less than 4n (DNA synthetic) during which the DNA content
has doubled (Ormerod, 1999).

The experimental groups consisted o f cells treated with three concentrations o f
Arglabin-DMA (15.25 and 30.50 pM). Also, 19.5 pM 5-Fluorouracil was used for a
positive control to demonstrate correctly stained cells and cell cycle effects. 5Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting
thymidylate synthetase. Treatment o f cells with 5-FU leads to an accumulation o f cells in
S-phase (Takeda et al., 1999). Cells which were not subjected to any treatment with the
drug were used as a negative control. HCT 116 and HT-29 cells were seeded at a density
o f 2 x 104 cells/cm2. After 24 hours incubation in a CO 2 incubator, the media in the flasks
were replaced with fresh media or with media containing Arglabin-DM A (15.25 and
30.50 pM) or 5-Fluorouracil (19.5 pM). The cells were incubated for a further 24 hours.

For each time interval, a cell pellet was obtained by centrifugation o f floating
cells and attached cells. The pellet was then washed once with 1 x PBS (0.14 M NaCl; 3
mM KC1; 10 mM Na 2 HPO; 2 mM KH 2 PO 4 , pH 7.2). It was fixed in 70% ethanol and
stored at 4 °C. At the time o f processing, a pellet was obtained by centrifugation o f the
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samples at 2000 r.p.m. for 5 minutes. The resulting pellet was washed once with 1 x PBS
and then resuspended in 3 ml o f 1 x PBS.

100 pi o f 0.5 mg m l'1 RNase was added to each sample. The samples were
incubated at 37 °C for 30 minutes. The samples were then stained with 40 pi o f 0.5 pg
m l'1 propidium iodide. All samples were filtered through a 40 pM pore mesh to protect
the nozzle o f the flow chamber in cytometer. The samples were analyzed using two
different flow cytometers: a FACSCalibur flow cytometer (Becton-Dickinson
Biosciences: Immunocytometry Systems, San Jose, CA, USA) at Eastern Virginia
Medical School or the Coulter EPCICS C clinical flow cytometer (Beckman Coulter,
Miami. EL, USA) at Old Dominion University.

13. STATISTICAL ANALYSIS

We used three different final inoculation cell densities (4 x 103, 2 x 104, or 4 x
104 cells/cm2). Cell growth in HCT 116 or HT-29 was tested with the addition o f three
different concentrations (15.25, 30.50, or 45.75 pM) o f Arglabin-DMA for three different
durations (1, 2, or 3 days) o f incubation. Data under the same conditions were collected
and analyzed. Samples chosen from data o f untreated HCT 116 or HT-29 cells were
compared as control groups with data from cells treated with Arglabin-DMA in HCT 116
or HT-29. The data files were analyzed using Adventures in Statistics 7.0 (SPSS,
Syracuse, NY. USA). Statistical analysis shows that the critical t-value (teal) is greater
than the observed t-values (t table), with the probability value (P-value).
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First, differences in all test results between decreased cell numbers in HCT 116 or
HT-29 after treatment with Arglabin-DMA were analyzed by a 2-tailed Student's t test.
We hypothesize that the decrease in total cell growth numbers after treatment with
Arglabin-DMA in HCT 116 or HT-29 is not significantly different. The student t test was
used to compare mean values, and statistical significance was achieved when P <0.05.
Second, a Paired Student's t test was performed to compare both the percentage of
decreased cell numbers between HCT 116 and HT-29. The null hypothesis is that there
are no difference in growth inhibition between HCT 116 (ras-; K -ras mutant) and HT-29
(ras +; wide type ras) after exposure o f Arglabin-DMA. The cut-off level for statistical
significance o f differences was predetermined as P <0.05 for all comparisons.
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RESULTS

1. REEXAMINATION OF THE ABILITY OF ARGLABIN-DMA TO INHIBIT
FARNESYLATION OF RAS PROTEIN I N VITRO.

1.1. Cell Viability

In our studies, three concentrations (15.25, 30.50, and 45.75 pM ) o f ArglabinDMA were used. Two cell lines o f different ras status, HCT 116 and HT-29, underwent
similar cell rounding and detachment after treatment with Arglabin-DMA (Figure 9 and
10). Distribution o f floating cells in HCT 116 and HT-29 was calculated from sixteen cell
culture data sets. The range o f floating cells per ml for HCT 116 after exposure o f three
different concentrations of Arglabin-DMA was 1.76 - 6.76 x 104 and for HT-29 it was
2.50 - 5.66 x 104 in a dose-dependent manner. The percentages o f floating cells to total
cell number was 8-39% , and 9-32% , respectively (Table 3).

About 4 x 104 cells/cm2 were examined after 24hrs, because the population
doubling times o f both HCT 116 and HT-29 after exposure with Arlabin-DMA are about
24 hours. Cells were cultured for three more days. After incubation with no drug (control)
and three different concentrations o f Arglabin-DMA, total cell numbers in HCT 116 or
HT-29 decreased in direct relation to the concentration of Arglabin-DMA (Figure 11),
and three different concentrations (15.25, 30.50 or 45.75 pM) o f Arglabin-DMA led to a
reduction in cell numbers o f 24.5%, 58.3%, and 66.2% in HCT 116, and by 11.8%,
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Figure 9 Morphology o f floating cells and adherent cells in HCT 116. Adherent cells
show anchorage-dependent growth, whereas floating cells show rounding and detachment
after treatment with Arglabin-DMA (black arrow (->) indicates floating cell; gray arrow
(
) indicates attached cells).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

60

Figure 10 Morphology o f floating cells and adherent cells in HT-29. Adherent cells
show anchorage-dependent growth, whereas floating cells show rounding and detachment
after treatment with Arglabin-DMA (black arrow (-*) indicates floating cell; gray arrow
(
) indicates attached cells).
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Table 3 Distribution of floating cells in HCT 116 and HT-29 after three different
concentrations (15, 30 or 45 p.M) o f Arglabin-DMA (Floating cells: rounding and
detached cells)___________________________________________________________
Floating cells

Mean (Cells/ml)

Range (Cells/ml)

HCT 116

3.54 x 104

1.76 - 6.76 x 104(8-39% )

HT-29

3.74 x 104

2 .5 0 -5 .6 6 x 104 (9-32% )
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Figure 11 Inhibition of cell growth after exposure to Arglabin-DMA in HCT 116 or
HT-29 cells. (C: untreated drug (Control), 15A: 15.25 pM Arglabin-DMA, 30A: 30.50
pM Arglabin-DMA, 45A: 45.75 pM Arglabin-DMA).
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67.4%, and 69.1% in HT-29 relative to the control values (Figure 12). Arglabin-DMA
thus inhibits the proliferation o f both cultured human colon tumor cells (HCT 116 and
HT-29), having different ras status in vitro. It is probable that reduction in cell number
after treatment with Arglabin-DMA is not affected by ras status.

Changing the cell number in the inoculation produced a significantly different
result in regards to cell growth. Three different inoculation cell sizes (4 x 103, 2 x 104,
and 4 x 104 cells/cm2) were used. Cell growth in HCT 116 or HT-29 was tested with the
addition o f three different concentrations o f Arglabin-DMA (Figure 13 and Table 4).
Also, the percentage o f inhibition o f cell growth in each group o f the various
concentrations o f Arglabin-DMA was calculated by comparing the untreated group and
the Arglabin-DMA treated group (Figure 14 and Table 5). It was determined that
inhibition o f cell growth was directly related to the concentration o f Arglabin-DMA, and
inversely related to the total cell number o f inoculation in both HCT 116 and HT-29.
Arglabin-DMA inhibits tumor cell growth in a dose-dependent manner. Also, no
difference is seen between cell lines based on Ras status.

Although many anticancer drugs have been developed that have proven to inhibit
the growth o f cancer cells in vitro, many o f these treatments involve chemicals that may
also injure normal cells in cancer patients, resulting in impaired cell functioning. Serious
harm to normal cells by anticancer drugs is an important problem in the development o f
drugs. After 72 hours o f incubation with several positive controls (30.50 pM Arglabin-
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Figure 12 Percentage o f cell growth inhibition after exposure o f Arglabin-DMA in
HCT 116 and HT-29 cells. (15A: 15.25 pM Arglabin-DMA, 30A: 30.50 pM ArglabinDMA, 45A: 45.75 pM Arglabin-DMA).
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Figure 13 Percent inhibition o f cell growth between inoculation numbers and
concentrations of Arglabin-DMA in the HCT 116 cell line. (15A: 15.25 jaM ArglabinDMA, 30A: 30.50 (aM Arglabin-DMA, 45A: 45.75 |aM Arglabin-DMA).

Table 4 Percent inhibition o f cell growth between inoculation numbers and
concentrations o f Arglabin-DMA in the HCT 116 cell line
HCT 116 (cells/cm2)
30A
45A
15A
4 x 10J
97.40%
88.58%
100%
2 x 104
35.02%
74.31%
84.39%
4 x 104
62.13%
69.10%
12.15%
(15A: 15.25 jaM Arglabin-DMA, 30A: 30.50 ^iM Arglabin-DMA, 45A: 45.75 |aM
Arglabin-DMA).
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Figure 14 Percent inhibition o f cell growth between inoculation numbers and the
concentrations o f Arglabin-DMA in the HT-29 cell line. (15A: 15.25 pM Arglabin-DMA,
30A: 30.50 pM Arglabin-DMA, 45A: 45.75 pM Arglabin-DMA).

Table 5 Percent inhibition of cell growth between inoculation numbers and the
concentrations o f Arglabin-DMA in the HT-29 cell line
HT-29 (cells/cm2)
15A
4SA
30A
4 x 10J
97.09%
99.53%
95.81%
2 x 104
91.74%
41.60%
70.94%
4 x l®4
16.04%
29.18%
69.10%
(15A: 15.25 pM Arglabin-DMA, 30A: 30.50 pM Arglabin-DMA, 45A: 45.75 pM
Arglabin-DMA).
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DMA, 19.5 pM 5-Fluorouracil, 10 pM Lovastatin, or 58 nM Taxol), Arglabin-DMA was
examined to investigate relative toxic effects in normal cells (Hs27, fibroblast) in
comparison with these other drugs.

Cell growth after exposure to Arglabin-DMA in HCT 116 or HT-29 cell lines was
significantly inhibited: 79.13% or 77.06% decrease in total cell numbers, respectively
(Figure 15, 16). Taxol in HCT 116 and HT-29 inhibits 84.20% and 78.40% o f cell growth.
5-Fluorouracil in HCT 116 and HT-29 inhibited 64.57% and 69.31% cell growth.
Arglabin-DMA, 5-FU, and Taxol thus significantly inhibit cell growth in both human
tumor cell lines. In contrast, HCT 116 cells treated with Lovastatin decresase 52.39%,
while HT-29 had only a slight decrease (19.01%) in cell growth. Our study showed that
Lovastatin is thus highly effective in mutant K-ras HCT 116 cells, but not in normal ras
HT-29 cells. The inhibition of cell growth due to treatment with Arglabin-DMA is similar
to that o f Taxol, and slightly greater than 5-FU and Lovastatin. Statistical analysis o f cell
growth inhibition between each drugs compared with Arglabin-DMA in HCT 116 or HT29 cell lines showed that Arglabin-DMA affects cell growth inhibition as that o f Taxol or
5-FU and is more effect than Lovasatin (Figure 15, 16).

In a normal cell line (Hs27), cells treated with Lovastatin or Taxol decreased cell
survival by 68.71% and 57.82% after three days o f incubation. The 5-FU treated group
was reduced 43.30%. Arglabin-DMA inhibited 41.58% cell growth in Hs27. Statistical
analysis showed that the probability value o f both Taxol and Lovastatin compared with
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Arglabin-DMA cytotoxicity in HCT 116 after three days incubation. (30.50
|iM Arglabin-DMA, 19.5 jaM 5-Fluorouracil, 10 |iM Lovastatin, 58 nM Taxol).
4: P= 0.202, Taxol vs. Argalbin-DMA.
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Figure 16 Arglabin-DMA cytotoxicity in HT-29 cell line after three days incubation.
(30.50 |oM Arglabin-DMA, 19.5 p.M 5-Fluorouracil, 10 p.M Lovastatin, 58 nM Taxol).
♦
: P= 0.833, Taxol vs. Arglabin-DMA.
♦ 4
: P= 0.268, 5-Fluorouracil vs. Arglabin-DMA.
♦ + + : P= 0.010, Lovastatin vs. Arglabin-DMA.
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Arglabin-DMA in HCT 116 or HT-29 cell lines are smaller than 0.05; in contrast, the
probability value, compared with 5-Fluorouracil, showed greater than 0.05 (Figure 17).
Therefore cell growth inhibition o f Arglabin-DMA in normal Hs27 is less than that of
Lovastatin or Taxol, and is similar to that o f 5-FU. After three or eight days incubation
with Arglabin-DMA or Taxol, it was found that the viability o f Hs27 cells treated with
Arglabin-DMA had increased from 41.38% to 53.01%. The groups treated with Taxol
had a more dramatic decrease in total cell growth (68.97% to 85.79%) (Figure 18 and
Table 6). This signifies that normal cells (Hs27) are less susceptible to Arglabin-DMAinduced toxicity, and the drug has less potential for inhibiting normal cell growth,
particularly after longer exposures.

1.2. Statistical analysis

Changing the cell number o f the inoculation, the concentration o f drug, or the
incubation time in both human colon tumor cell lines (HCT 116 or HT-29) produced
significantly different results in regards to cell growth and viability.

To examine whether Arglabin-DMA inhibits specifically mutant K-ras tumor
colon cells or not, statistical analysis was executed to analyze cell culture data obtained
from each experiment. The results o f the t test for both HCT 116 and HT-29 were
significant when cell lines treated with Arglabin-DMA were compared to the untreated
control (Table 7). Therefore, cell growth inhibition by Arglabin-DMA in HCT 116 or
HT-29 has a significant effect. Also, we compared toxicity in HCT 116 and HT-29 after
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Figure 17 Cytotoxicity in Hs27 after three days incubation with four anticancer drugs.
(30.50 |jM Arglabin-DMA, 19.5 |iM 5-Fluorouracil, 10 (j,M Lovastatin, 58 nM Taxol).
+
: P= 0.028, Taxol vs. Arglabin-DMA.
♦ ♦
: P= 0.073, 5-Fluorouracil vs. Arglabin-DMA.
♦ ♦ ♦ : P= 0.007, Lovastatin vs. Arglabin-DMA.
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Untreated (Day 3 incubation)

Untreated (Day 8 incubation)

Arglabin-DMA (Day 3 incubation)

Arglabin-DMA (Day 8 incubation)

Taxol (Day 3 incubation)

Taxol (Day 8 incubation)

Figure 18 The morphological cell changes in Hs27 after two different incubation
periods (three or eight days) after treatment with Arglabin-DMA or Taxol. (A and B:
Untreated-control group, C and D: 30 pM Arglabin-DMA, E and F: 58 nM Taxol).
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Table 6 Percentage o f cell growth inhibition in Hs27 after two different incubation
periods (three or eight days) after treatment with Arglabin-DMA or Taxol
______
Hs27
Day 3 (cells/cm2)
Day 8 (cells/cm2)
5.24 x 104
1.10 x lO5
Control
3.06
x
104
(41.38%)
5.16
x 104 (53.01%)
30 pM Arglabin-DMA
1.62 x 104 (68.97%)
58 nM Taxol
1.56 x 104 (85.79%)
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Table 7 Statistical analysis o f decline o f the total cell number between control group
and Arglabin-DMA group

A
t-test for Equality o f Means

HCT 116
Two sample test
Control - Drug

t cai.
3.488

t table
2.0322

P-value
0.001

Ho: Uj = Uj
Reject Ho

B
HT 29
Two sample test
t cai.
Control - Drug
2.105
A: HCT 116 cell line, B: HT-29 cell line.

t-test for Equality of Means
t table
2.0322

P-value
0.043

Ho: Uj = Uj, (Uj = Hypothetical value)
t table = A),05(2). df, (df = n-1, n=sample number)
11 cai | < t table (P>0.05) then do not reject Ho
I t cai. | ^ t table (P<0.05) then reject Ho
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exposure to Arglabin-DMA (Table 8) and found that there was no significant difference
in toxicity between the two cell lines (HCT 116 or HT-29). Therefore, statistical analysis
indicated that Arglabin-DMA equally affects cell growth inhibition in both wild-type ras
and mutant K-ras tumor cells.

1.3. Add-Back experiments

Higher doses o f Lovastatin, Manumycin A, and Arglabin-DMA at 90% inhibitory
concentrations for HCT 116 were used in these experiments to clarify the inhibiting
potential o f these drugs. Total cell numbers o f HCT 116 (ras-) after Lovastatin treatment
were decreased by 79.89%, but only 32.92% in HT-29 (ras+). In the group treated by
both famesyl pyrophosphate and Lovastatin in HCT 116 and HT-29, the number o f viable
cells decreased in comparison to the only Lovastatin treated group. In contrast, the group
treated by both geranylgeranyl pyrophosphate and Lovastatin in HCT 116 significantly
increased cell growth (85.99%) compared to the data o f Lovastatin treated group (20.11%)
(Figure 19). Also, detached HCT cells induced by Lovastatin were reattached in the
group treated by both geranylgeranyl pyrophosphate and Lovastatin in HCT 116 cell
(data not shown). In HT-29, cell growth rate in between the group treated by Lovastain
and the group treated by geranylgeranyl pyrophosphate and Lovastatin changed 65% to
82% (Figure 19). T h e geranylgeranyl pyrophosphate slightly prevented the cell growth
inhibition by Lovastatin. These data imply that geranylgeranyl pyrophosphate prevented
Lovastatin-induced cell rounding and detachment, suggesting that Lovastatin may act by
inhibiting geranylgeranylation and not famesylation o f target proteins. Manumycin A
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Table 8 Statistical analysis o f the percent o f decrease in cell number between HCT 116
and HT-29 cell lines after treatment with Arglabin-DMA____________________________
t-test for Equality of Means

Cell line
Paired test
HCT 1 1 6 -H T -2 9

t cai.
1.562

t table
2.1098

Sig.(2-tail)
0.137

Ho: Uj = 0
t table = *0 .0 5 (2 ), df, (df = n-1, n=sample number)
11 cai I < t table (P>0.05) then do not reject Ho
I t cai. | > t table (P<0.05) then reject Ho
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Figure 19 Add-back experiment after treatment with Lovastatin. Lovastatin in both
HCT 116 and HT-29 after three days incubation inhibits polyprenylation and the
formation o f isoprenoids. (famesyl pyrophosphate and geranylgeranyl pyrophosphate).
(L: 30 pM Lovastatin, M: FPP: 100 pM Famesyl pyrophosphate, GGPP: 10 pM
geranylgeranyl pyrophosphate).
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was chosen because FPP is a substrate not only for FTase but also for other enzymes
catalyzing the synthesis o f squalene and other prenylation reactions and is expected to
affect the isoprenoid biosynthetic pathway. The result is that Manumycin A did not affect
the groups with added isoprenoid (Figure 20). Significantly, in spite o f higher
concentration o f Manumycin A, it slightly affected FIT-29 cells (ras-) (24.25%)
compared to cell growth inhibition (5.34%) o f HCT 116 cells (ras+). Arglabin-DMA, in
contrast significantly inhibited cell growth in both colon tumor cell lines. Addition o f
isoprenoid (famesyl pyrophosphate or geranylgeranyl pyrophosphate) did not relieve
inhibition in either cell line (Figure 21). Therefore, Arglabin-DMA had no effect on the
isoprenylated proteins, and the data with Arglabin-DMA is similar to that o f Manumycin
A. In contrast, inhibition o f geranylgeranylation is the probable mechanism o f action o f
Lovastatin. These results cast doubt on the suggested FTI-based mechanism o f inhibition
for Arglabin-DMA.

2. TEST OF WHETHER ARGLABIN-DMA INHIBITS CANCER CELL
GROWTH IN AN APOPTOSIS-DEPENDENT MANNER.

2.1. Annexin V assay

We have observed that colon tumor cells lose their ability to maintain an
asymmetric lipid bilayer after exposure to Arglabin-DMA. The most pronounced feature
o f this normal asymmetry is the significant absence o f phosphatidylserine (PS) in the
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Figure 20 Add-back experiment after treatment with Manumycin A. Manumycin A in
both HCT 116 and HT-29 after three days incubation inhibits polyprenylation and the
formation o f isoprenoids. (famesyl pyrophosphate and geranylgeranyl pyrophosphate).
(M: 20 pM Manumycin A, FPP: 100 pM Famesyl pyrophosphate, G: 10 pM
geranylgeranyl pyrophosphate).
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Figure 21 Add-back experiment after treatment with Arglabin-DMA. Arglabin-DMA
in both HCT 116 and HT-29 after three days incubation inhibits polyprenylation and the
formation o f isoprenoids. (famesyl pyrophosphate and geranylgeranyl pyrophosphate).
(A: 61 pM Arglabin-DMA, FPP: 100 pM Famesyl pyrophosphate, GGPP: 10 pM
geranylgeranyl pyrophosphate).
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outer leaflet o f the plasma membrane. During the initial phase o f apoptosis, phospholipid
redistribution caused by membrane alterations is detected. When PS is exposed, Annexin
V binds specifically to the phospholipid membrane in the presence o f Ca2+ ions (Vermes
and Haanen, 1994). Apoptotic cells are distinguished by using Annexin V as an EGFP
(enhanced green fluorescent protein) conjugate in combination with propidium iodide
(PI). Annexin V-EGFP is the brightest green fluorescent reagent available for Annexin
V-based detection o f apoptosis (Koopman et al., 1994).

After being treated with 30 pM Arglabin-DMA in HCT 116 and HT-29, early
apoptotic cells with intact cell membranes stained green (Annexin V positive/PI negative)
were detected through photography at three days in floating cells (Figures 22 and 23).
Also, dimly stained green cells that did not have enough intensity to be detected by
photography were present in both attached and floating groups. Arglabin-DMA thus
induces apoptosis in floating cells that form phospholipid redistribution based on
membrane alterations. It is possible that apoptosis induced by Arglabin-DMA occurs in
attached cells, perhaps representing an early stages o f apoptosis that will be followed
later by detachment.

2.2. Apoptosis dye-uptake assay

Cell uptake o f a purple-red dye happens only in the apoptotic process (Figure 24).
Colon tumor cells (HCT 116 and HT-29) not treated with Arglabin-DMA did not exhibit
dye uptake. Small numbers of cells in the attached HCT 116 and HT-29 cells undergo
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Figure 22 Annexin V assay in HCT 116. Early apoptotic cells in floating cells, after
treatment with 30.5 pM Arglabin-DMA for three days incubation.
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Fignnre 23 Annexin V assay in HT-29. Early apoptosis in floating cells treated with 30.5
pM Arglabin-DMA for three days incubation.
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Figure 24 Image o f apoptotic cells in Apopercentage assay. HCT 116 and HT-29 cells
undergoing apoptosis have become visible by purple-pink dye. Black arrow (->)
indicates apoptotic cell.
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apoptosis after exposure to Arglabin-DMA. After one day incubation with ArglabinDMA, 13.39% o f floating HCT 116 cells were apoptotic. Under the same conditions,
29.43% o f floating group in HT-29 were apoptotic. At three days, over 26% o f floating
HCT 116 and HT-29 cells were apoptotic (Figures 25 and 26; Tables 9 and 10). Thus,
early phase apoptotic cells, stained by Apopercentage dye, were increased in ArglabinDMA induced floating cells on HCT 116 and HT-29.

2.3. Identification of dying cells by apoptotic nuclear morphology

Cells dying by apoptosis usually undergo characteristic morphological and
biochemical changes. The types o f morphological change consist o f membrane blebbing,
chromatin condensation, nuclear breakdown, and cytolysis into condensed apoptotic
bodies. Dramatic changes occur within the nucleus during apoptotic death (Vermes and
haanen, 1994). Cells undergoing apoptosis display increased chromatin condensation and
nuclear fragmentation. These morphological changes are triggered by the activation o f
members o f the caspase family including caspase activated DNase, and several novel
proteins including AIF (apoptosis-inducing factor) and CIDE (Cell death-inducing DFFlike Effector) (Kroemer and Zamzami, 1999). An apoptotic chromatin condensation
inducer in the nucleus, Acinus, induces apoptotic chromatin condensation. Acinus is
cleaved by caspase-3 and an additional unknown protease, generating a small active
peptide p i 7, which causes chromatin condensation in vitro (Sahara et al, 1999).
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Figure 25 Apoptosis dye-uptake assay in HCT 116. Percentage apoptotic cells after one
and three days incubation following treatment with 30.5 pM Arglabin-DMA.

Table 9 Apoptosis dye-uptake assay in HCT 116
Cell type
Incubation
Untreated
day
Group
Normal cells
1.23 x 10b
1 day
0 (0%)
Apoptotic cells
Normal cells
3 days

8.87 x 106

Apoptotic cells

0 (0%)

30A Attached
Group
5.33 x 10b
4.24 x 103
(0.80%)
1.06 x 106
4.35 x 104
(4.10%)

30A Floating
Group
1.27 x lO3
1.70 x 104
(13.39%)
1.98 x 105
5.16 x 104
(26.06%)

The number o f apoptotic HCT 116 cells.
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Figure 26 Apoptosis dye-uptake assay in HT-29. Percentage apoptotic cells after one and
three days incubation following treatment with 30 pM Arglabin-DMA.

Table 10 Apoptosis dye-uptake assay in HT-29
Incubation
Cell type
Untreated
30A Attaching
30A Floating
day_________________________ Group ________ Group _________ Group
4.74 x 105
Normal cells
1.45 x 10b
2.27 x 105
1 day
6.68 x 104
0 (0%)
Apoptotic cells
0 (0%)
(29.43%)
7.47 x 106
1.40 x 106
2.83 x 105
Normal cells
4.69 x 103
3 days
7.53 x 104
0 (0%)
Apoptotic cells
(0.34%)
(26.61%)
The number o f apoptotic HT-29 cells.
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Fluorescent DNA-binding dyes, such as ethidium bromide (EB), are taken up only
by dying cells. EB fluoresces a red-orange color under ultraviolet light and with increased
fluorescence when bound to double-stranded DNA. Metachromatic dye acridine orange
(AO) can be taken up by both live and dead cells, which can be distinguished by their
different morphologies. AO intercalates into DNA (green) and also binds to RNA (redorange). The difference in the uptake o f these two dyes (AO/EB) allows the identification
o f viable versus non-viable cells by fluorescence microscopy. An assay o f cell viability
based on simultaneous cell staining with AO and EB allows one to discriminate between
live vs. apoptotic vs. necrotic cells (Reed, 2000).

In Tables 11 and 12, over 95% HCT 116 or HT-29 cells not exposed to ArglabinDMA are live cells (Stage 1; Figure 27; A). After exposure to Arglabin-DMA, many
attached cells in HCT 116 or HT-29 cell line were live in Stage 1, while over 80%
floating cells in HCT 116 or HT-29 were in Stages 2 and 3 (Figures 27; B and C).
However, fewer than 8% o f attached cells in HCT 116 and HT-29 showed morphologies
classified as Stage 2 (Figure 27; B). Floating cells in HCT 116 and HT-29 after treatment
with Arglabin-DMA were identified as apoptotic cells in Stage 4, which includes bright
orange chromatin that is fragmented, or apoptotic bodies in the late phase o f apoptosis
(Figure 27; D). Red color cells, Stage 5, are dead cells, (Figure 27, C and E). The
increase o f dead cells in the untreated group is attributed to nutritional deficiencies in the
medium due to the increased growth o f colon tumor cells.
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Figure 27 Identification o f dying cells by apoptotic nuclear morphology. A: Stage one
- bright green chromatin with organized cell structure: viable cells with normal nuclei
(uniform distribution). B: Stage two - bright green chromatin that is highly condensed or
fragmented: viable cells with apoptotic nuclei, early phase o f apoptosis. C: Stage three or
four - bright orange chromatin (uniform staining) that is highly condensed or fragmented:
nonviable cells with apoptotic nuclei, late phase o f apoptosis. D: Stage four - bright
orange chromatin that is highly fragmented: nonviable cells with apoptotic nuclei, late
phase o f apoptosis. E: Stage five - red cell (lower left) that is a dead cell.
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Table 11 Identification o f dying cells by apoptotic nuclear morphology
HCT 116
TCN
Stage
1

2-3

4

5

Control Group

8.87 x 106

96.08%

negligible

none

3.92%

Attached Group

1.06 x 106

91.36%

7.41% (Stage 2)

none

1.24%

Floating group

1.98 x 105

2.59%

86.2%

4.31%

6.90%

Morphological changes after treatment with 30.5 pM Arglabin-DMA for three days
incubation in HCT 116. (TCN: Total cell number).
Stage
Stage
Stage
Stage
Stage

1=
2=
3=
4=
5=

Bright green chromatin with organized cell structure - Normal cells.
Bright green chromatin that is highly condensed - Early phase o f apoptosis.
Bright orange chromatin that is highly condensed - Late phase o f apoptosis.
Bright orange chromatin that is fragmented - Late phase o f apoptosis.
Red cells - Dead cells.
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Table 12 Identification o f dying cells by apoptotic nuclear morphology
HT-29
TCN
Stage
1

2-3

4

5

Control Group

7.47 x 106

95.74%

negligible

none

4.26%

Attached Group

1.40 x 106

56.60%

32.08% (Stage 2)

none

8.93%

Floating Group

2.83 x 105

4.35%

81.16%

11.59%

2.90%

Morphological changes after treatment with 30.5 pM Arglabin-DMA for three days
incubation in HT-29. (TCN: Total cell number).
Stage
Stage
Stage
Stage
Stage

1=
2=
3=
4=
5=

Bright green chromatin with organized cell structure - Normal cells.
Bright green chromatin that is highly condensed - Early phase o f apoptosis.
Bright orange chromatin that is highly condensed - Late phase o f apoptosis.
Bright orange chromatin that is fragmented - Late phase o f apoptosis.
Red cells - Dead cells.
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Typical early or late apoptotic morphological changes induced by ArglabinDMA were observed in the floating cells o f HCT 116 and HT-29 cell lines, including
evident cytoplasmic and nuclear shrinkage, chromatin condensation, and membrane
blebbing, which are all characteristic morphological alterations o f apoptosis (Figure 27; B,
C, and D). Also, early phase apoptotic cells, with bright green chromatin that is highly
condensed, were observed in the attached cells treated with Arglabin-DMA. Therefore,
Arglabin-DMA induced apoptosis in floating cells and to a lesser degree in attached cells.

2.4. TUNEL assay

The DNA strand-breaks o f the untreated group generated by TACS-Nuclease in
the positive control have uniform brown staining in HCT 116 or HT-29 (Figures 28). A
negative control sample omitted terminal deoxynucleotidyl transferase (TdT) in the
enzymatic reaction (not shown but very similar to Figure 29).

The attached group treated with Arglabin-DMA, in both colon tumor cell lines,
was no different than the negative control sample (Figure 29). This indicates that the
anchorage-dependent cells did not have the free 3-hydroxyl residues o f DNA fragments,
and apoptotic cells were not found in the attaching group after the exposure to ArglabinDMA. No apoptotic cells were detected in the untreated sample or the attached cells of
HCT 116 and HT-29 exposed to 30 pM Arglabin-DMA. The 10-30% floating cells could
not be monitored because anchorage-dependent cells were the only types examined.
These floaters are likely the apoptotic population.
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Figure 28 Positive control of TUNEL assay. DNA strand breaks generated by nuclease
in essentially every untreated cell were stained as brown color (A: HCT 116 B: HT-29).
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Figure 29 TUNEL assay in attached cells after treatment with 30.5 pM Arglabin-DMA
for three days (A: HCT 116 B: HT-29).
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2.5. Analysis of DNA fragmentation

As a positive control, we used Taxol since this drug induces morphological
changes like Arglabin-DMA and has the ability to induce apoptosis. As seen in DNA
fragmentation assays, in the floating cells in HCT 116 or HT-29, exposure to 58 nM
Taxol results in DNA ladder formation within one day, whereas fragmentation was
absent in the untreated sample or the attached sample exposed to 30 pM Arglabin-DMA
(Figure 30 and 32). However, after Arglabin-DMA or Taxol treatment, DNA
fragmentation increased in the floating HCT 116 cells after three days o f incubation
(Figure 31). Similarly in the floating HT-29 cells, DNA ladder bands were detected
similar to HCT 116 (Figure 33). Lovastatin induced morphological changes like
Arglabin-DMA in HCT 116. The floating HCT 116 cells showed ladder bands after three
days o f incubation (Figure 34). DNA fragmentation was still not detectable in the
untreated sample, or drug treatment (Arglabin-DMA or Taxol) in the attached cells of
ether cell line. Cell death induced by Taxol was more rapid than by Arglabin-DMA.

Data from the DNA fragmentation assay showed that floating cells had undergone
apoptosis. In an additional experiment, we examined the relationship between p53 and
apoptosis. Taxol and Lovastatin were used as positive controls for this experiment. In
previous studies, Taxol was shown to display p53-independent apoptosis. (Lanni et al.,
1997; O'Connor et al., 1997). Lovastatin has been shown to induce p53-dependent
apoptosis in human colon tumor cells (Agarwal et al., 1999). After exposure to ArglabinDMA, Lovastatin, or Taxol in each o f the cell lines, HCT 116, HT-29 and Hs27, we
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Fngunir© 3® Analysis o f DNA fragmentation in HCT 116 after 24 hours incubation with
30.5 |jlM Arglabin-DMA or 58 nM Taxol. (M: Molecular Marker; 1 kb plus DNA ladder,
1: Control-untreated cells, 2: Attached cells treated with Arglabin-DMA, 3: Floating cells
treated with Arglabin-DMA, 4: Attached cells treated with Taxol, 5: Floating cells treated
with Taxol).
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Figure 31 Analysis o f DNA fragmentation in HCT 116 after three days incubation with
30.5 (iM Arglabin-DMA or 58 nM Taxol. (M: Molecular Marker; 1 kb plus DNA ladder,
1: Control-untreated cells, 2: Attached cells treated with Arglabin-DMA, 3: Floating cells
treated with Arglabin-DMA, 4: Attached cells treated with Taxol, 5: Floating cells treated
with Taxol).
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Fngunir® 32 Analysis o f DNA fragmentation in HT-29 after one day incubation with 30.5
|j,M Arglabin-DMA or 58 nM Taxol. (M: Molecular Marker; 1 kb plus DNA ladder, 1:
Control-untreated cells, 2: Attached cells treated with Arglabin-DMA, 3: Floating cells
treated with Arglabin-DMA, 4: Attached cells treated with Taxol, 5: Floating cells treated
with Taxol).
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F igure 33 Analysis o f DNA fragmentation in HT-29 after three days incubation with
30.5 (iM Arglabin-DMA or 58 nM Taxol. (M: Molecular Marker; 1 kb plus DNA ladder,
1: Control-untreated cells, 2: Attached cells treated with Arglabin-DMA, 3: Floating cells
treated with Arglabin-DMA, 4: Attached cells treated with Taxol, 5: Floating cells treated
with Taxol).
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Figure 34 Analysis o f DNA fragmentation in two human colon tumor cell lines after
three days incubation with 10 pM Lovastatin. (M: Molecular Marker; 1 kb plus DNA
ladder, 1: Control-untreated cell o f HCT 116, 2: Attached cell treated with Lovastatin in
HCT 116, 3: Floating cell treated with Lovastatin in HCT 116, 4: Control-untreated cells
o f HT-29 5: Attached cells treated with Lovastatin in HT-29, 6. Floating cells treated
with Lovastatin in HT-29).
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counted the number o f floating cells in each drug group. Both HCT 116 and Hs27 cells,
having wild-type p53, showed increased numbers o f floating cells after exposure to
Lovastatin. The number o f floating cells decreased significantly within the HT-29 cell
line (p53 mutant) after treatment with Lovastatin in comparison with HCT 116 or Hs27
cell lines. Taxol, however, proved to increase the number o f floating cells in all three cell
lines. After exposure to Arglabin-DMA, the number o f floating cells that resulted was
shown to be similar to the number o f floating cells after treatment with Taxol in all three
cell lines (Table 13). The number o f floating cells with Lovastatin in HT-29, having
mutant p53, decreased abruptly. This indicates that Lovastatin may induce p53-dependent
apoptosis. The numbers o f floating cells o f the three cell lines treated with ArglabinDMA were similar to that o f floating cells exposed to Taxol, which induces p53independent apoptosis. This implies that Arglabin-DMA may induce p53-independent
apoptosis.

3. TESTING WHETHER ARGLABIN-DMA INDUCES CELL CYCLE ARREST
IN HUMAN COLON TUMOR CELL LINES.

3.1. Flow cytometry analysis of the cell cycle

In analysis o f the cell-cycle profile, each phase o f the cell cycle was displayed
with respect to DNA content. Thus, flow cytometry analysis o f DNA content revealed
whether Arglabin-DMA treated cells arrest in G 2 /M.
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Table 13 The relation between p53 and floating cells undergoing apoptosis
Hs27 (Ras+, p53+)
HCT 116 (Ras-,
HT-29 (Ras+, p53-)
Cell types
P53+)
2.51 x 105 (9.46%)
Arglabin-DMA 5 x 104 (6.53%)
2.08 x 10s (11.35%)
1.19 x 104 (1.27%)
1.98 x 105 (27.12%) 7.63 x 105 (18.26%)
Lovastatin
4.07 x 105 (16.23%)
6.7 x 104 (13.99%)
3.07 x 105 (22.13%)
Taxol
Three cell lines (HCT 116, HT-29 and Hs27), either wild-type or mutated p53, were
grown to subconfluence, exposed to the respective drugs (30.5 jjM Arglabin-DMA, 10
pM Lovastatin or 58 nM Taxol) for 3 days and the number o f floating cells was counted.
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As shown in Figure 35 and Table 14 using a FACSCalibur (Becton-Dickinson
flow cytometer) at Eastern Virginia Medical School, untreated HCT 116 cells exhibited a
typical cell cycle distribution (72.31% in Gi, 20.26% in S phase, and 7.43% in G 2 /M
phase). When those were exposed to 19.5 pM 5-FU as a positive control, we observed
48.58% in Gi, 48.70% in S phase, and 2.72% in G 2 /M phase. Therefore, 5-FU reduces the
number o f cells entering the G 2 /M phase o f the cell cycle as compared to the untreated
sample. 15. 25 pM or 30.5 pM Arglabin-DMA treatment altered the cell cycle o f the
HCT 116 cells, arresting them in G 2 /M phase. In data from the Becton-Dickinson flow
cytometer, the Arglabin-DMA treated group again showed an increased yellow peak
(tetraploid: 4n) in the G 2 /M phase (Figure 35).

After exposure 15.25 pM Arglabin-DMA in the HCT 116 cell line, using the
Coulter flow cytometer, the data showed that the result is an increase in cells blocked at
G 2 /M phase (Figure 36 and Table 15). The results that HCT 116 cells treated with
Arglabin-DMA showed the arrest o f G 2 /M phase at 24 hours is similar to the results of
Becton-Dickinson flow cytometer. In Coulter flow cytometric analysis in HT-29 cells,
cells with two different concentrations o f Arglabin-DMA accumulated in G 2 /M by 24
hours and decreased Gi and S phase population (Figure 37 and Table 16).

In summry, analysis with two different instruments showed flow cytometry
profiles o f nuclear DNA content that revealed that Arglabin-DMA altered the DNA
content and induced a G 2 /M phase arrest o f cell cycle in HCT 116 and HT-29 cells.
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Figure 35 DNA content frequency histograms o f HCT 116 from a FACSCalibur
(Becton-Dickinson flow cytometer). A: Untreated group, B: 15.25 p M Arglabin-DMA,
24 hrs, C: 30.5 p M Arglabin-DMA, 24 hrs, D: 19.5 pM 5-FU. The red peak on the Gi or
the G 2 /M phase represents diploid cells. The yellow peak (tetraploid: 4n) is showed on
the G 2 /M phase o f B and C graphes in Arglabin-DMA treatment group.
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T able 14 Flow cytometry analysis o f cell cycle in HCT 116 from a FACSCalibur
(Becton-Dickinson flow cytom eter)_______________ ________________________
HCT 116
g 2/ m
S
G,
A. Untreated (Control)
20.26 %
72.31 %
7.43 %
32.72 %
42.38 %
24.90 %
B. 15.25 p,M Arglabin-DMA
37.78 %
28.57 %
33.65 %
C. 30.5 pM Arglabin-DMA
48.70 %
48.58 %
2.72%
D. 19.5 pM 5-Fluorouracil
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Figure 36 DNA content frequency histograms o f HCT 116 from the Coulter EPCICS C
clinical flow cytometer. A: Untreated group, B: 15.25 pM Arglabin-DMA, 24 hrs.
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Table 15 Flow cytometry analysis o f cell cycle in HCT 116 from the Coulter EPCICS C
_____________________________________________________
clinical flow cytometer
HCT 116
S
g 2/ m
G,
25.85 %
A. Untreated (Control)
46.70 %
27.45 %
26.54 %
15.54%
57.92 %
B. 15.25 piM Arglabin-DMA
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Figure 37 DNA content frequency histograms o f HT-29 from the Coulter EPCICS C
clinical flow cytometer. A: Untreated group, B: 15.25 pM Arglabin-DMA, 24 hrs, C:
30.5 pM Arglabin-DMA, 24 hrs.
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Table 16 Flow cytometry analysis o f cell cycle in HT-29 from the Coulter EPCICS C
clinical flow cytometer_______________________________________________________
HT 29
S
g 2/ m
G,
A. Untreated (Control)
26.63 %
45.58 %
27.79 %
15.28%
69.27 %
B. 15 (J.M Arglabin-DMA
15.45%
23.61 %
54.54 %
C. 30 \iM Arglabin-DMA
21.85%
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DISCUSSION

A previous study suggested that Arglabin-DMA, modified to render it watersoluble, is a FTI that inhibits the binding o f famesyl diphosphate (FDP) to FTase, thus
inhibiting famesylation o f Ras protein, and that Arglabin-DMA inhibits anchorageindependent growth o f mouse neuroblastoma cells as well as KNRK cells (a normal rat
kidney [NRK] cell line transformed by Kirsten murine sarcoma virus) (Shaikenov et al.,
2001). Our results showed that Arglabin-DMA has a marked effect on the morphology
and the growth o f both mutant K-ras and wild-type ras human colon tumor cell lines
(HCT 116 and HT-29), and these effects occur in a concentration-dependent manner.
Cytotoxicity results, compared between the two colon tumor cell lines, suggested that
those tumors that were sensitive to Arglabin-DMA were not dependent on Ras function
activated by mutated K-ras. This means that Arglabin-DMA as an FTI does not
specifically affect the activated Ras.

Preclinical studies on the response o f cultured human tumor cells to FTI treatment
showed that several cell types with wild-type ras are sensitive to FTIs, both in vivo and in
vitro (Cox, 2001). In other studies, about 50% o f K-ras transformed cell lines were
observed to be as resistant as nontransformed cell lines, although it was very easy and
straightforward to inhibit both processing and transformation as a result o f oncogenic HRas (Rowell et al., 1997). Proteins ending with a serine, such as H-Ras, bind more
weakly to FPTase than proteins having a methionine, such as Ki4B-Ras and lamin B
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(Reiss el al., 1991). The differences in affinity imply that proteins in cells have different
sensitivities to an FTI (Gibbs and Oliff, 1997). The basis for the resistance o f K-Ras to
FTIs is that its affinity for the FTase enzyme is high (Rowell et al., 1997). It has been
reported that K-Ras processing could escape FTI inhibition; nevertheless, tumors
containing mutated K-ras could be inhibited by FTIs (Sepp-Lorenzino et al., 1995).

Another possible mechanism based on the cytotoxic data that Arglabin-DMA
affects the growth o f HCT 116 and HT-29 cell lines is that it affects the famesylation o f
one or more non-Ras proteins. It means that Arglabin-DMA may affect inhibition o f the
processing o f other famesylated proteins. Famesylated proteins clearly have important
roles to play in normal cells. Among the known famesylated CAAX proteins other than
Ras, the G-proteins (for example, rap-1, rab, and rho), lamin A and B, and inositol
triphosphate 5-phosphatase type I may have relevance to intracellular signaling and
apoptosis (Yeung et al., 2000). The nuclear lamins essential for nuclear structural
integrity (Dalton et al., 1995), proteins o f the retinal visual signal transduction system
(transducin y subunit, cGMP phosphodiestrase a , and rhodopsin kinase) (Gibbs et al.,
1994), the human homologue o f the yeast molecular chaperone YDJ1 (Caplan et al.,
1992), the skeletal muscle phosphorylase kinase, as well as other proteins yet to be
identified or whose precise function is unknown (for example Pxf, RhoE, and Rap2)
(Foster et al., 1996) are all thought to be famesylated (Gibbs and Oliff, 1997).
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In previous studies, researchers found that FTIs inhibit the famesylation o f one or
more non-Ras proteins such as Rho B to exert their anti-tumor effects (Cox, 2001;
Rowell et al., 1997; Whyte et al., 1997). Protein prenylation is catalyzed by three
different enzymes that recognize both the isoprenoid and the acceptor protein: FTase
(famesyl transferase) and GGTase (geranylgeranyl transferase) I and II (Casey and
Seabra, 1996). However, the specificity o f these enzymes for their substrates is not
absolute. Thus, it appears that proteins usually modified by geranylgeranyl pyrophosphate
(GGPP) may be prenylated by famesyl pyrophosphate (FPP) and vice versa, given the
appropriate circumstances (Guijarro et al., 1998). Previous investigations into the
biologic mechanism o f the growth inhibition o f Ras-transformed cells have shown that
famesylation o f K-Ras and N-Ras is more resistant to FTase inhibitors than famesylation
o f H-Ras (James et al., 1995; Nagasu et al., 1995; Sun et al., 1998). In the absence o f
FTase inhibitors, all Ras proteins are present only in the famesylated form. However, KRas and N-Ras (but not H-Ras) become geranylgeranylated by GGTase I in vivo in a
dose-dependent manner when intracellular famesylation is inhibited by an FTase
inhibitor (Rowell et al., 1997; Whyte et al., 1997). Subsequently, both FTase and
GGTase I inhibitors are required for inhibition o f K-Ras processing (Lemer et al., 1997;
Sun et al., 1998). Like K-rasB and N-ras, the low-molecular-weight protein Rho B also
can be either famesylated or geranylgemylated (Armstrong et al., 1995; Casey and
Seabra, 1996). Recently, it has been suggested that the antitransforming effects o f FTIs
are mediated at least in part by alteration o f famesylated Rho proteins, including RhoB
(Adjei, 2001; Chen et al., 2000; Lebowitz and Prendergast, 1998). In contrast to Ras
proteins, RhoB exists normally in vivo in a famesylated (RhoB-FF) and a
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geranylgeranylated version (RhoB-GG). Treatment with FTIs results in a loss o f RhoBFF and a gain o f RhoB-GG (Du et al., 1999).

Arglabin-DMA also affected the growth o f normal cells. Our studies show that
this drug blocks the growth o f tumor cells, irrespective o f ras genotype, with limited
toxicity toward normal cells (Hs27). It has been reported in the literature that FTIs can be
less growth inhibiting in normal cells in vitro and have fewer side effects in animal and
human studies (Kohl et al., 1993; Rowinsky et al., 1999). FTI treatment inhibits and
reverses malignant transformation without severely affecting normal cells (Du and
Prendergast, 1999). Interestingly, tumor cell lines with wild-type Ras were also sensitive
to FTI. In contrast, nontransformed epithelial cell lines were far less sensitive. It has been
suggested that nontransformed cells may produce a form o f Ras that is isoprenylated even
in the presence o f FTase inhibitors (Nagasu et al., 1995; Emanual et al., 2000).
Additionally, this phenomenon may be due to functional redundancy within the Ras
family (Reuter et al., 2000). The genetic ablation o f FPTase does not cause the yeast cells
to die. These observations provided evidence that inhibition o f FPTase, even though it is
important to the function of a number o f proteins other than Ras, would not be toxic to
normal cells (Gibbs and Oliff, 1997).

Preclinical studies showed that Arglabin-DMA, a sesquiterpene y-lactone,
competitively inhibits the binding o f famesyl diphosphate to FTase and may inhibit the
function o f other famesylated cell proteins such as rho and related cytoskeletal proteins
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(Shaikenov et al., 2001). Our studies with add-back experiments examinated the possible
explanation that Arglabin-DMA, as a sesquiterpene y-lactone, may affect the synthesis o f
cholesterol and suppress protein prenylation, particularly inhibition o f FTase and the
oncogenic activated ras protein. Geranyl pyrophosphate and famesyl pyrophosphate,
respectively, are intermediates in the synthesis o f monoterpene and sesquiterpenes (Elson,
1995). It is been reported that the monoterpene, limonene, and the sesquiterpene, (3lonone, suppress HMG-CoA reductase activity and lower the level o f low-density
lipoprotein (LDL) cholesterol (Crowell et al., 1991), causing differentiation o f tumor
cells (Haag et al., 1992). The secondary action o f assorted isoprenoids is the direct
inhibition o f the protein isoprenyl transferase activities. These isoprenoids markedly
suppress the growth o f tumors in vitro and in vivo; the growth o f the host animal is not
impaired (Elson, 1995). Arteminolide, a sesquiterpene lactone from Artemisia rulvatica,
shows selective inhibitory activity against rat FTase (Lee et al., 1998).

Our data from add-back experiments proved that Lovastatin acts by inhibiting
geranylgeranylation and not famesylation o f target proteins. Lovastatin induced an
accumulation of unmodified Ras and caused an up-regulation o f both RhoB and Rapl A
(Holstein et al., 2001). HMG-CoA reductase inhibitors, including Lovastatin, decrease
the overall synthesis of final products derived from the isoprenoid biosynthetic pathway,
including cholesterol, dolichol and ubiquinone (Corsini et al., 1995). In one study,
researchers examining the effects o f Manumycin A, an FPP analogue, found that the
mechanism o f action of Manumycin A did not involve the biosynthesis o f intermediates
o f the cholesterol biosynthetic pathway and did not affect the synthesis o f cholesterol
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(Nagase et al., 1996). Furthermore, Manumycin A is cytotoxic and induces apoptosis in a
human cell line derived from a colorectal cancer which expresses a wild-type K-ras gene
(Di Paolo et al., 2000; Yeung et al., 2000). This effect is obtained by inhibition o f ras
famesylation that reduces signal transduction through the MAPK (the mitogen-activated
protein kinase)/ERK (Signal-related kinase) pathway, without affecting protein
geranylgeranylation or the synthesis o f final products o f the cholesterol synthesis (Di
Paolo et al., 2000). The analysis o f add-back experiments in HCT 116 or HT-29 cells
showed that Manumycin A, as a famesylation inhibitor, had no effect, similar to the
results o f Arglabin-DMA on protein famesylation and geranylgeranylation. It was shown
that Arglabin-DMA did not affect the biosynthesis o f end products o f isoprenoid
metabolism, and the effect of Arglabin-DMA on cell growth does not require the
presence o f a mutated ras gene. Although results with two FTIs (Manumycin A and
Arglabin-DMA) in add-back experiments were not modified specifically by either FPP or
GGPP, it may also be possible that Arglabin-DMA, as a non-FTI, may have anti-tumor
effects. However, we can not conclude that Arglabin-DMA had no effect on famesylation;

One would predict that Arglabin-DMA may inhibit the growth o f tumor cells by
blocking signaling pathways emanating from Ras. One o f the best characterized o f these
pathways is the MAPK cascade, which is activated following Ras/Raf interaction, or via
the phosphatidylinositol 3-kinase (PI 3-kinase; PI(3)K) pathway. Small G proteins such
as Ras, Rho, and Rac have been shown to regulate a wide spectrum o f cellular functions,
including cytoskeletal organization, membrane trafficking, transcriptional activation, and
cellular transformation (Gibbs and Oliff, 1997; Porter et al., 1998). Many types of
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extracellular signals, especially those involving activation o f receptor tyrosine kinase and
integrin receptors, trigger activation o f small G proteins, which in turn activate a variety
o f signalings. Ras, which is frequently mutated in human tumors, activates several
signaling pathways, including the Raf/mitogen-activated protein kinase cascade and the
PI 3-kinase/Akt pathway, resulting in malignant transformation in rodent fibroblasts (van
Weering et al, 1998; Jiang et al., 2001).

Protein famesylation, catalyzed by a FTase, plays important roles in the
membrane association and protein-protein interaction o f a number o f eukaryotic proteins.
Recent development of FTase inhibitors (FTIs) has led to further insight into the
biological significance o f famesylation in cancer cells. A number o f reports point to the
dramatic effects FTIs exert on cancer cells. These can be classified into four distinct
categories. First, FTIs inhibit anchorage-independent growth o f a wide variety o f cancer
cells (James et al., 1993; Kohl et al., 1993). Second, FTIs may cause Go/Gi cell cycle
arrest, G 2 /M cell cycle arrest, or have no effect on cell cycle progression changes,
depending on the cell line examined (Vogt et al., 1997). Third, FTIs induce apoptosis o f
cancer cells when the cells are exposed to low serum conditions or are inhibited in their
attachment to the extracellular substratum (Tamanoi et al., 2001). Four, FTIs are reported
to affect the actin cytoskeleton and cell morphology (Suzuki et al., 1998; Tamanoi et al.,
2001). Clinical trials of FTIs are not complete; thus, how they selectively inhibit
malignant cell growth remains uncertain. Our studies showed that in many respects,
Arglabin-DMA looks like other chemical FTIs, but not as a FTI inhibiting famesylation.
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Given all these considerations, the potential role o f Arglabin-DMA in the inhibition of
tumor cell growth certainly deserves further investigation.

A striking morphological effect o f Arglabin-DMA is its ability to cause cells to
round up and detach in both colon tumor cell lines (HCT 116 and HT-29). Annexin V
and Apoptosis dye-uptake assays were applied to detect early apoptotic cells with altered
membranes to cause translocation o f phosphatidylserine molecules to the exterior surface
o f the cell membrane. These assays detected a significant increase in apoptotic cells in
the floating group when compared to other groups (untreated group or attached group
exposed with Arglabin-DMA). Although early phase apoptotic cells were detected in the
attached groups in the Annexin V assay, these were not documented through photography
due to the fact that the cells were dimly stained. However, the Apopereentage assay was
used to show more effectively that the membrane had been altered and that early phase
apoptosis occurred in attached cells.

During the late phase o f apoptosis, specific endonucleases create DNA fragments
with double-stranded breaks, cleaving them into so-called domain-sized fragments (50300 bp). The TUNEL assay allowed for identification of fragmented DNA. These assays
showed that untreated cells or adherent cells treated with Arglabin-DMA did not exhibit
this late apoptosis phenotype. As seen in the DNA fragmentation assay, Arglabin-DMA
induces DNA fragmentation in the late phase o f apoptosis in floating but not attached
HCT 116 and HT 29 cells. After exposure to Arglabin-DMA in one o f apoptosis-
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detection assays, identification o f dying apoptotic cells, early and late phase o f apoptotic
cells increased greatly in the floating group, and nucleic in the early phase o f apoptosis
were seen in the attached group. This demonstrated the ability o f Arglabin-DMA to
induce the early and late apoptosis in floating cells and the early phase o f apoptosis in
attached cells. We did not conclusively determine whether or not detection o f apoptosis
in floating cells is due to cells detaching, or if the detaching cells were the result o f
apoptosis. However, measurement o f cell viability after Arglabin-DMA challenge shows
that the early-detached cells can reattach upon replating in the absence o f Arglabin-DMA
and grow identically to untreated control cells (data not shown). This suggests that
apoptosis precedes detachment. The results indicate that the early phase apoptotic cells
affected by Arglabin-DMA in the two colon tumor cell lines probably were detached and
then preceded to the late phase o f apoptosis. Therefore, Arglabin-DMA may lead to
apoptosis, then to changes in the adherence properties o f cells, causing them to be shed
from the substrate prior to identifiable apoptosis. This apoptosis may contribute to the
antitumor effects o f Arglabin-DMA in vivo.

We propose that the growth matrix-detached fraction o f HCT 116 or HT-29 cells
treated in vitro with Arglabin-DMA were apoptotic. The results suggest that this
apoptosis, in response to the loss o f cell-to-cell and/or cell-to-matrix communication,
may be analogous to "anoikis," (Frisch and Francis, 1994). Anoikis is the term for
detachment-induced cell death: cells undergo apoptosis upon disruption o f the
interactions between integrins and proteins o f the extracellular matrix. Integrins are
receptors that bind extracellular matrix proteins to the outside o f the cell. The
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extracellular matrix is responsible for tissue organization throughout the body. It is also
becoming clear that matrix proteins regulate certain aspects o f gene expression and the
cell cycle. They also regulate apoptosis in epithelial cells (Frisch and Francis, 1994).
Anoikis also occurs when epithelial cells are either not bound to the matrix via integrins,
or bind to the wrong integrins (Boudreau et al., 1995).

The tumor suppressor gene, p53, regulates apoptosis following a variety o f stress
stimuli (Bennett, 1999). P53-dependent apoptosis activates the apoptosome, a multimeric
complex consisting o f Apaf-1, cytochrome c, dATP/ATP and procaspase-9, via the socalled intrinsic pathway (Soengas et al., 1999). Our data demonstrated that floating cells
exposed in vitro to Arglabin-DMA enter apoptosis. To examine the relationship between
p53 and apoptosis, we proposed that Arglabin-DMA may induce p53-independent
apoptosis. The drug may be able to induce an extrinsic pathway o f apoptosis or may
mediate a cross-talk mechanism between the apoptosis pathways, through Bid, one o f the
Bcl-2 family. It was reported that epithelial cells undergo death receptor-dependent
apoptosis when detached from the matrix, a process termed anoikis. Also, the cleavage o f
Akt/protein kinase B (PKB) by death receptor signaling contributes to anoikis (Bachelder
et al., 2001). Anoikis was found to be activated through the Fas pathway by FasL, the socalled extrinsic pathway. FasL/Fas interaction, Fas-FADD complex formation, and
caspase-8 activation precede the bulk o f anoikis in endothelial cells, and inhibition o f any
o f these events blocks anoikis (Aoudjit and Vuori, 2001). Other results have indicated
that the death receptor adaptor molecule, FADD, may be involved in anoikis, as a
dominant-negative truncated FADD, containing only the death domain, inhibits anoikis.
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Anoikis was also shown to be accompanied by an early activation o f caspase-8, as would
be expected for death receptor activation (Frisch and Screaton, 2001).

In epithelial cells o f the intestine and other organs, activated Ras induces
resistance to anoikis (Shao et al., 2000). Resistance to anoikis may facilitate the survival
o f cancer cells during systemic circulation, aiding the formation o f metastases (Douma et
al., 2004). The nature o f the survival signals activated by integrin engagement and
usurped by oncogenic Ras are still unclear. Recent studies have implicated that adhesion
or transformation by ras oncogenes have been shown to protect epithelial cells from
apoptosis through activation o f PI 3-kinase and Akt/PKB (Khwaja et al, 1997). A Rho
family member, Rac 1, inhibits anoikis in epithelial cells. Rac 1-mediated cell survival
strongly depends on PI 3-kinase activity. PI 3-kinase, acting through Akt/PKB, a
subfamily o f serine/threonine protein kinases, is implicated as a key mediator o f the
aberrant survival of Ras-transformed epithelial cells in the absence o f attachment, and
mediates matrix-induced survival o f normal epithelial cells (Coniglio et al., 2001; Frisch
and Francis, 1994). Recently, the neurotrophic receptor tyrosine kinase (RTK), TrkB,
was identified as a potent and specific suppressor o f caspase-associated anoikis and
linked it to the promotion of metastases. TrkB triggered the activation o f PI 3-kinases
which stimulate Akt/PKB, and this too was active in the TrkB-producing cells. The result
was a blockade of caspase-associated anoikis and related forms o f cell death. PI 3-kinases
also drive numerous other cellular functions associated with metastasis (Liotta and Kohn,
2004; Douma et al., 2004). It would be o f interest to characterize Trk B effects in the
Arglabin-DM-treated cells.
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In general, inhibition o f cell growth by FTI in human tumor cells results in Go/Gi
cell cycle block, G 2 /M cell cycle arrest, or has no effect on cell cycle progression (Vogt et
al., 1997). One aspect o f FTI biology that is poorly understood is the ability o f these
drugs to induce cancer cell growth arrest at the G 2 /M phase o f cell cycle (Mazzocca et al.,
2003). In the present study, both human colon tumor cell lines showed cell accumulation
at the G 2 /M phase o f the cell cycle following Arglabin-DMA treatment. Flow cytometry
results indicated that these cells were tetraploid. Effective growth inhibition by FTI L744,832 correlated with the accumulation o f cells with a tetraploid (4n) DNA content and
high levels o f cyclin Bl/cdc2 kinase activity, implying cell cycle arrest downstream from
the DNA damage-inducible G 2 /M cell cycle checkpoint (Song et al, 2000). Treatment of
a lung cancer cell line (A-549) with the protein famesyl transferase inhibitor Lonafamib
(SCH66336) resulted in an increase o f G 2 /M phase cells. It was shown that prophase and
metaphase cells accumulated (Jiang et al., 2000). The inhibition o f CENP-E famesylation
by FTI results in the alteration o f the microtubule-centromere interaction during mitosis
and results in the accumulation o f cells prior to metaphase (Ashar et al., 2000). It would
be that Arglabin-DMA may associate with proteins involved to cell cycle or other
famesylation proteins to induce human colon cancer cell growth arrest at the G 2 /M phase
o f cell cycle.

As discussed previously, Arglabin-DMA appears to induce apoptosis in a p53independent manner; p53, a tumor suppressor protein, acts also in late Gi phase. If DNA
damage has occurred, p53 accumulates in the cell nucleus and induces the p21-mediated
inhibition o f cyclin D/cdk. Mdm2, by facilitating the nuclear export/inactivation o f p53,
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becomes part o f an inhibitory feedback loop that inactivates p21 -mediated Gi arrest. p53
prevents the cell progressing to the S phase (Momand et al., 2000). Also, p53 participates
in the regulation o f G2/M. The progression into M phase requires Cdc2 which can be
inhibited by p21 (Cyclin dependent kinase inhibitor), GADD45 (a p53-regulated stress
protein), or 14-3-3a (adapter pro tein ). p53 regulates the expression o f these inhibitory
proteins to induce growth arrest (Hermeking et al., 1997; Liu and Kulesz-Martin, 2001).
Both cell lines, having different Ras and p53 status, similarly induce cell cycle arrest at
the G 2 /M phase. It is therefore assumed that Arglabin-DMA may affect the arrest o f
G 2 /M phase in cell cycle without involvement o f the p53 protein.

In flow cytometry analysis after the exposure o f Arglabin-DMA for one day, our
results did not show DNA content characteristic o f apoptotic cells (e.g., position o f the
sub-Gi peak on the DNA content frequency histograms). In analysis o f DNA
fragmentation, the floating groups, after treatment with Taxol in HCT 116 or HT 29 cells,
showed ladder bands o f DNA after one day incubation. However, DNA ladder bands
were not found in the floating group with Arglabin-DMA. It may be reasoned that flow
cytometry analysis does not show the sub-Gi peak on DNA content frequency histograms.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

123

CONCLUSION

We conclude that Arglabin-DMA has specific cytotoxic effects in the two human
colon tumor cell lines and in comparison to other antitumor drugs, less cytotoxicity to
normal cells in vitro. Also, the drug has a marked effect on the morphology and the
growth o f both mutant K-ras and wild-type ras human colon tumor cell lines. ArglabinDMA does not affect the biosynthesis o f the cholesterol pathway. Our studies do not
support that Arglabin-DMA acts to inhibit tumor cell growth as a FTase inhibitor. One
possible explanation is that Arglabin-DMA may inhibit the processing o f other
famesylated proteins or may block signaling pathways emanating from Ras. However, it
certainly deserves further attention. In our studies, Arglabin-DMA induces apoptosis after
cellular rounding and detachment as a striking morphological effect in human colon
tumor cell lines. The mechanism involved may be anoikis as cells undergo apoptosis
upon disruption o f the cell-matrix interaction. This apoptosis is induced in a p53independent manner. It may also be induced via an extrinsic (death receptor) pathway.
Finally, Arglabin-DMA induces G 2 /M cell growth arrest in human colon tumor cell lines
(HCT 116 and HT-29). The utility o f this drug in combating cancer remains an attractive,
possibility, although more work will be required to elucidate its mechanism o f action.
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